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Abstract 
 
Gestational diabetes and maternal obesity are associated with impaired maternal 
glycaemic control and increased risk of delivering a macrosomic fetus. Macrosomic as 
well as growth restricted neonates have an increased risk of metabolic syndrome and 
cardiovascular disease in adult life which may be mediated through an altered intra-uterine 
environment. The placenta acts as a mediator between the mother and the fetus and 
handles placental nutrient exchange and transfer. Insulin-like growth factors 1 and 2 (IGF1 
and IGF2) are hormones similar to insulin and are known for their growth promoting 
function in the body. They are also present in the placenta and play an important role in 
regulating placental and fetal growth. Animal and human studies have shown that IGF1 
and IGF2 deletions are associated with growth restriction. The IGFs are bound to their 
binding proteins called insulin-like growth factor binding proteins (IGFBPs) which 
modulate their bioavailability and can therefore modulate fetal growth.  The IGFs and 
IGFBPs are associated with glucose regulation but their role in gestational diabetes is 
unclear. We hypothesized that the placental gene expression of IGF system related genes 
is altered in pregnancies complicated by fetal growth disorders (pregnancies with small or 
large fetuses) and in those women who had gestational diabetes mellitus (GDM) or 
increased body mass index (BMI>30).  
Epigenetics is the study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence. DNA methylation is an 
epigenetic mechanism which involves addition of methyl group to a cytosine base in the 
DNA forming a methylated cytosine-phosphate-guanine (CpG) dinucleotide which is 
known to silence gene expression. This can potentially alter the expression of IGFs and 
their binding proteins. We have also hypothesized that a relationship existed between 
DNA methylation and gene expression of components of the IGF axis in the placenta.  
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The placental IGF1 expression was found to be reduced in women with small for 
gestational age (SGA) neonates. The expression of IGFBPs was upregulated in SGA 
neonates and downregulated in large for gestational age (LGA) neonates. The placental 
IGF1 gene promoter was found to be hypermethylated while the promoters of the binding 
proteins were hypomethylated in the placentas of SGA neonates. The umbilical cord levels 
of IGF1 and the binding proteins in SGA and LGA neonates showed a similar trend to the 
placental gene expression changes. We have also analysed the placental gene expression 
and umbilical levels of imprinted gene GRB10 which has been investigated in mice 
studies and is known to cause growth restriction. We found increased placental expression 
of GRB10 and hypomethylation of its promoter in SGA neonates. The placental 
expression of IGF1, IGFBP1 and IGFBP2 was found to be decreased in women with 
GDM on diet and on metformin but not in those on insulin. The IGF1, IGFBP1 and 
IGFBP2 promoters were noted to be hypermethylated but only in women on diet treatment 
and not on metformin on insulin. The umbilical levels of IGF1 and IGFBP1 but not 
IGFBP2, were increased in GDM thus showing an inverse trend to the placental gene 
expression changes. In conclusion our results suggest that in SGA neonates, changes in 
CpG methylation contribute to the changes in gene expression of components of the IGF 
axis and GRB10 in fetal growth disorders. Differential methylation of the IGF1 gene, its 
binding proteins and GRB10 is likely to play a role in the pathogenesis of SGA neonates. 
Our results also suggest that GDM is associated with gene expression and epigenetic 
alterations in the IGF1, IGFBP1 and IGFBP2 genes, which could be part of the wider 
metabolic complexities associated with GDM. 
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1.1. Fetal programming – Overview 
The association between fetal growth disorders and its implications on diseases in adult life 
dates back as early as 1928 (1) where predisposition to diabetes in oversized babies was 
noticed. Environmental changes also have a significant effect on phenotype wherein to enable 
survival, internal resources are optimised albeit putting individuals at risk of diabetes and 
heart disease. This was observed by Neel in 1962 (2) who proposed the ―thrifty genotype 
hypothesis‖ where thrifty genes selected during feast-or-famine periods would increase fat 
storing capacity in scarcity but increase the risk of insulin resistance when food became 
abundant. About three decades later correlations between fetal growth patterns and diseases 
like hypertension, ischemic heart disease, reproductive disorders, etc. were brought to 
attention by Barker and colleagues in 1992 (3). They proposed the ―Thrifty phenotype 
hypothesis‖ in 2001 (4) according to which the fetus survives in a nutritionally deprived 
environment by ensuring the growth of vital organs like brain is maintained at the expense of 
other organs. These adaptive changes which are suited on a nutritionally deprived 
environment in utero become detrimental postnatally in adult life with the abundance of 
nutrition. The fetal response according to the nutrient supply and maternal environment is in 
accordance with the expectation of a similar environment postnatally. However since this is 
not always the case, this disparity makes the fetus prone to diseases in later life (5–8).  This 
association of adverse long term effects in life due to deleterious environmental effects in 
early life was referred to as ―programming in utero‖ although the term ―developmental or 
environmental plasticity‖ is now more recently preferred (9). One of the well-known 
examples is the development of glucose intolerance in adults whose mothers were exposed to 
malnutrition during the 1944-1945 Dutch famine (10). Malnutrition especially during late 
gestation was shown to be linked to permanent impairment of insulin-glucose metabolism in 
adult life and that occurred even if the fetal effects of malnutrition were minimal. Different 
cells in our body are programmed for different functions despite carrying the same DNA 
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sequences implying that there are other mechanisms at play which are responsible for this 
(11). In fact the common key finding of research in different fields of behavioural 
development, ecology, molecular biology, life history, and medical epidemiology is that a 
given genotype gives rise to varied phenotypes depending on different environmental 
conditions (12). Therefore not all changes in gene function can be explained solely by a 
change in DNA or gene expression and several mechanisms are capable of affecting gene 
function without altering the underlying DNA sequence. This is called Epigenetics (Epi – 
Greek – outer/above/over) which is a study of these mechanisms, known to influence gene 
function through DNA methylation, genomic imprinting, histone modification and small 
RNA mediated control (13).   
 
1.2. Role of insulin - like growth factors and its binding proteins in fetal growth 
 
Insulin-like growth factor 1 (IGF1) and insulin – like growth factor 2 (IGF2) are two 
homologous hormones encoded by the their genes located on chromosome 12 and 11 
respectively (14). They play an important role in cellular growth in all systems, both 
prenatally and postnatally and continue to have anabolic effects in adult life (15). The 
IGFs bind to the insulin – like growth factor 1 receptor (IGF1R) and Insulin Receptor-A 
(IR-A) and multiple signalling pathways are activated. These induce different functions 
such as cell growth and differentiation, glucose metabolism and cell survival (16) (Figure 
1.1). The IGFs are bound to insulin-like growth factor binding proteins (IGFBPs). All the 
IGFBPs have conserved N and C-terminal domains which are thought to bind with IGFs 
and a variable midregion (17).  Seven IGFBPs have been identified namely IGFBP1 to 
IGFBP7 (17). The genes encoding IGFBP1 and IGFBP3 are encoded on chromosome 7, 
IGFBP2  and IGFBP5 on chromosome 2, IGFBP3 on chromosome 7, IGFBP6 on 
chromosome 12 and IGFBP7 on chromosome 4 respectively (18). The IGFBPs form 
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binary complexes with IGFs except IGFBP3 which forms a ternary complex of 
approximately 140kDa with acid-labile subunit (ALS) (19). The IGFBPs reduce the 
bioavailability of the IGFs and therefore negatively affect the downstream events of the 
IGF signalling pathway (Figure 1.2).  
 
 
 
     
Figure 1.1 The IGF signalling pathway. IGF1 and IGF2 bind to IGF1R in the cell membrane which 
initiates the AKT pathway and all the downstream events like protein synthesis, glucose metabolism, cell 
proliferation and cell survival. The IGF2 binds to mainly the IGF2R which is a clearance receptor and is not 
involved in signalling. 
 
 
 
 
Protein 
synthesis 
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While growth hormone (GH) is the major growth hormone, it plays little or no role in 
regulating growth in the fetus (20). Human placental GH replaces pituitary GH in pregnancy 
and is the main driver of IGF production in the placenta (21). Although both IGF1 and IGF2 
are expressed in fetal tissues from zygote formation and implantation until birth, IGF2 
expression is more extensive than IGF1 in fetal tissues from mid to late gestation (22). There 
is a rapid rise in IGF1 levels postnatally as a result of GH stimulation. Maternal IGF1 has 
been shown to stimulate fetal growth by increasing the transfer of nutrients to the fetus 
through the placenta (23). Fetal IGF1 is presumed to stimulate fetal growth by promoting 
anabolic events and DNA synthesis in fetal tissues (24). IGF1 gene ablation has been shown 
to reduce fetal weight in mice while IGF1 administration has shown to increase fetal weight 
but not placental weight (25). Although more abundant than IGF1, IGF2 mRNA decreases 
with gestation (26) and appears to play a role in cellular growth and tissue-specific cell 
proliferation (27). IGF2 overexpression in mice causes placental and fetal overgrowth, 
whereas IGF2 gene deletion reduces placental weight by 17%, with a fetal weight reduction of 
40% (28,29). When both genes are deleted simultaneously, the effects on fetal growth are 
additive (30). Human placental studies describing IGF1 expression in SGA neonates have 
given variable results with some showing a  higher expression of IGF1 (31,32) while some 
showing a lower expression (33,34). The IGFs and IGFBPs are known to co-localise in the 
placenta and together play a crucial role in regulating fetal growth. The affinity of IGFBP3 for 
IGFs is higher than other IGFBPs (35) hence approximately 80-90% of IGFs are bound to 
IGFBP3 in a ternary complex (36).  However, in pregnancy the IGFBPs are cleaved by 
proteases which reduces their affinity for IGFs (37). Proteases have been identified for 
IGFBP2, IGFBP3, IGFBP4 and IGFBP5 but not for IGFBP1 (38). As a result maternal 
IGFBP1 continues to increase during pregnancy in a similar fashion to IGF1 (39). IGFBP1 is 
most abundantly found in the decidua and the placental bed as compared to other binding 
proteins (26). Furthermore, IGFBP1 affinity towards IGF1 is 3 times higher than proteolyzed 
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IGFBP3 but its affinity for IGF2 is lower (36). Hence proteases shift the IGF control from 
IGFBP3 to IGFBP1 in pregnancy. IGFBP1 is considered more important for short term 
regulation of  IGF bioactivity as it fluctuates in response to insulin and carbohydrate intake 
(40). Increased placental expression of IGFBP1 has been associated with  fetal growth 
restriction (41). IGFBP2 has been reported to be most abundant in syncytiotrophoblast (42) 
and its umbilical cord levels have been shown to have an inverse relationship with fetal 
growth (43). The relationship between IGFBP3 and birth weight is not clear. Some 
researchers have reported lower umbilical IGFBP3 levels in SGA neonates (44) while some 
have reported lower levels of IGFBP3 taken from neonatal serum from SGA neonates on the 
1
st
 day of life (45). However another group found significantly higher levels umbilical serum 
levels of IGFBP3 in SGA neonates (46). Like IGFBP1, IGFBP4 is also thought to be 
abundant in the placenta (26). Increased maternal serum IGFBP4 levels in the first trimester 
have been associated with later development of growth restriction (47) but there are scarcity 
of data on its placental expression and umbilical levels in fetal growth disorders. IGFBP5 and 
IGFBP6 have been found mainly in the decidua (42). IGFBP7 has been recently found to be 
an important regulator of trophoblastic proliferation and invasion (48) but its expression in 
human term placenta has not been investigated.  
 
 
1.3. Role of insulin - like growth factors and its binding proteins in gestational   
      diabetes mellitus  
 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance that begins or is 
first recognized during pregnancy (49). GDM is associated with long term risk of type 2 
diabetes, cardiovascular disease, obesity and metabolic syndrome (50). Pederson’s hypothesis 
suggests that maternal hyperglycaemia results in fetal hyperglycaemia which in turn causes 
fetal pancreatic islet tissue hypertrophy and insulin hypersecretion (51). Although 
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hyperinsulinaemia is the most important cause for adverse effects of GDM, the role of the 
IGF axis in mediating the actions of insulin in the intrauterine environment is still unclear. 
The placenta undergoes several alterations in diabetes and these alterations are dependent on 
factors such as duration of hyperglycaemia, quality of glycaemic control and duration of 
treatment (52). The placenta adapts to the maternal environment by buffering maternal 
glucose or altering the vascular resistance in an attempt to normalise fetal growth. However 
diabetic insults on the trophoblasts result in increased surface area, villous 
hypervascularisation and vascular dysfunction (53,54). As a result, the placenta can no longer 
mount an adequate response to the hyperglycemic maternal environment and fetal 
overgrowth occurs. Since the fetal-maternal vasculature in the placental villi is in contact 
with not only maternal blood but also fetal blood, the fetus is exposed to the maternal diabetic 
environment. There is evidence that the diabetic milieu results in significant changes in the 
expression of various placental inflammatory and growth markers (55). The IGF axis is 
regulated by nutrition which is under the direct control of glucose and insulin (30,56,57). 
IGFs which have a close structural homology to insulin (58), can bind to IGF receptors as 
well as insulin receptors and this may explain a role the role of IGFs in glucose homeostasis. 
Although maternal IGFs do not cross the placenta (59) they are known to increase placental 
glucose transport and fetal amino acid concentration (25,60). Therefore maternal IGFs are not 
only important in diverting nutrients to the fetus thus promoting fetal growth but IGF1 gene 
inactivation in mice liver has also shown to be associated with a decrease in IGF1 
concentrations, hyperinsulinemia and insulin insensitivity (58). There have been very few 
studies investigating maternal or fetal IGF levels in GDM.  Luo et al found elevated maternal 
serum and umbilical levels of IGF1 but not IGF2 (61) while Luthman et al (62) did not find 
any difference in the maternal serum IGF1 levels in GDM. Increased umbilical cord IGF1 
levels in GDM was noted in three studies (61,63,64) but there is scarcity of data regarding 
umbilical cord IGF2 levels. IGFBP1, apart from being the most important binding protein in 
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pregnancy, also plays a crucial glucoregulatory role. While the long term IGF activity is 
regulated by the larger ternary complex, the short term regulation of IGFs is by IGFBP1 (65). 
IGFBP1 is different from other IGFBPs  because it is regulated by metabolic milieu (66) and 
is powerfully suppressed by insulin (67) and carbohydrate levels (68,69).  IGFBP2 levels are 
thought to be affected by chronically high insulin levels, but not by acute changes in insulin 
as observed with IGFBP1 (70). IGFBP3 acts as a glucoregulatory protein since it’s involved 
in the long term regulation of IGF and is also known to bind to a nuclear receptor, 9 -cis 
retinoic acid receptor-alpha (RXR- α). The RXR-α  interacts with the peroxisome proliferator 
activated receptor-gamma (PPAR-γ ), a nuclear protein involved in the regulation of glucose 
and lipid metabolism (71,72). A recent human study has shown maternal circulatory levels of 
IGFBP1, IGFBP6 and IGFBP7 levels to be lower in GDM and umbilical cord IGFBP1, 
IGFBP2, IGFBP3 and IGFBP7 to be lower in GDM as compared to normal controls (73) 
However there is still scarcity of data investigating maternal and fetal IGFBPs in women with 
GDM.  
 
1.4. Role of insulin-like growth factors and its binding proteins in women with increased       
      body mass index in pregnancy 
 
The IGF axis is known to play a pivotal role in cellular growth and differentiation and 
glucose homeostasis (74). It is possible that the IGF axis regulates nutrient influx through the 
placenta in women with increased body mass index (BMI). It has been postulated that IGF1 
stimulates the differentiation of preadipocytes by regulating IGFBPs. Lower serum levels of 
IGFBP1 have been shown to be associated with chronic weight gain and could be playing a 
role in modulating IGF1 (75).  It is known that IGFBP3 modulates the bioavailability of IGFs 
however IGFBP3 has also been shown to inhibit adipocyte differentiation (76). Although the 
role of IGFBP4 is unclear, it is involved in stem cell differentiation into muscle and fat and 
therefore may be altered in pregnancy and weight gain (77). One study has shown reduced 
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IGFBP4 in the umbilical cord blood of women with increased BMI as compared to women 
with normal BMI (78). They did not find any difference in maternal IGF1, IGF2, IGFBP1, 
IGFBP3 and IGFBP4 and cord blood IGF1, IGF2, IGFBP1 and IGFBP3 in women with 
increased BMI. However there is dearth of data investigating the expression of IGF system 
related genes in pregnancies with increased maternal BMI and in infants.   
 
1.5. Epigenetic Mechanisms   
 
Epigenetics studies changes in gene expression caused by mechanisms other than changes in 
the underlying DNA sequence (79). The epigenetic changes are inherited through cell 
division in the form of a cellular memory (80) and may explain the different functions of 
numerous cell types despite an identical genome in our body. Epigenetic mechanisms permit 
genes to alter their expression in response to environmental cues without needing to undergo 
a structural change. During development epigenetic marks exhibit short term or long term 
flexibility, i.e. some epigenetic marks are removed with few cell divisions (short term 
flexibility) while some are maintained for many divisions (79,81). Epigenetic marks can 
adapt throughout life to environmental stimuli and therefore epigenetic alterations can lead to 
pathologies in adult life like diabetes and cancer. There are 3 main methods of epigenetic 
regulation namely DNA methylation, histone modification and non-coding RNA control.  
 
1.5.1. DNA methylation   
 
The most studied epigenetic mechanism is DNA methylation. DNA methylation involves 
adding a methyl group to the 5
th
 position of cytosine next to a guanine (CpG dinucleotide). 
This addition is catalysed by a group of enzymes called DNA methyltransferases (DNMTs) 
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which uses S-adenosylmethionine as a methyl donor (82) converting the cytosine to methyl-
cytosine (Figure 1.2).  
 
 
 
 
 
 
 
 
                      
 
 
Figure 1.2 Schematic representation of conversion of cytosine to 5’ methyl-cytosine. DNMT catalyses the 
conversion of cytosine to 5’ methyl-cytosine by transferring the methyl group from SAM to cytosine. DNMT = 
DNA methyltransferase, SAM = S – adenosylmethionine, SAH = S – adenosylhomocysteine, CH3 = Methyl 
group.  
 
DNMT1 is responsible for maintenance methylation while DNMT3A and DNMT3B are 
responsible for denovo methylation (83). DNA methylation is known to silence gene 
expression (84). There are two theories explaining this: first, methylation prevents binding of 
transcription factors, and second, methylation recruits methyl-CpG-binding proteins (MBPs) 
which indirectly represses chromatin state (85). There are about 28 million CpGs in the 
CH3 
DNMT 
SAMCH3 
SAH 
Cytosine 
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DNMT converts cytosine to 
5’methyl-cytosine  
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haploid human methylome of which about 70% are methylated (86). CpGs are clustered in 
specific regions called CpG islands which are often found in gene promoters. While the CpGs 
outside these islands are generally methylated those within the islands are predominantly 
unmethylated (82,84). This exception underlines the importance of DNA methylation and its 
role in transcriptional silencing.  
 
1.5.1.1. DNA methylation and embryonic development   
 
The evolution from zygote to an adult involves multiple phases of reprogramming and 
differentiation which are guided by various transcription factors as well as epigenetic 
alterations (81). As the primordial germ cells enter the genital ridge there is global 
demethylation followed by de novo methylation thus establishing sex specific imprints. 
Subsequently by the implantation stage the DNA methylation is erased. The exception to this 
are specific regions such as imprinted regions (87) which resist demethylation. After the 
blastocyst stage, de novo DNA methylation is re-established and the imprint marks are 
carried forward into the adult (Figure 1.3).  
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Figure 1.3 Pattern of DNA methylation in embryonic development. When the primordial germ cells enter 
the gonadal ridge all DNA methylation patterns are erased. Paternal and maternal methylation is re-established 
during male and female gamete differentiation. Post-zygotic demethylation occurs thus preparing the embryo for 
genetic reprogramming before the onset of DNA replication. After the blastocyst stage de novo methylation 
occurs in a lineage dependent manner which is then maintained postnatally into adult life. 
 
1.5.1.2. DNA methylation in the placenta   
 
Placental methylation is unique, in that the overall methylation level is significantly lower as 
compared to other somatic tissues (88–90). This hypomethylation is a special feature of the 
mammalian placenta and has been associated with providing nourishment and sustaining the 
fetus throughout gestation (91–93). The importance of placental DNA methylation has been 
proven in various animal studies for e.g. single dose infusion of demethylating agent 5-aza-
2’deoxyxytidine causes trophoblastic disruption in pregnant rats (94,95); placental 
hypermethylation in cloned cats is associated with decreased cloning success (96) and 
cytochrome P450 gene is controlled by variable placental methylation in sheep and cattle 
(97). Human studies as early as 1986 have demonstrated the effects of site-specific 
methylation on the binding capacity of the DNA binding protein and its effects on 
transcription (98). Aberrant placental methylation has been implicated in various pathologies 
such as gestational trophoblastic disease (99), pre-eclampsia (100), vitamin D alterations at 
the fetomaternal interface (101). These studies have shown that DNA methylation could be a 
potential marker of placental function. 
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1.5.2. Genomic imprinting   
 
Normally two copies of a gene are inherited one each from the mother and the father and 
usually both copies are functional. In certain genes one copy is inactive or silent. However, 
which copy is inactive or silent depends on the paternal or maternal inheritance. This is called 
―genomic imprinting‖. Genomic imprinting is an epigenetic phenomenon defined as the 
differential expression of a gene or chromosomal region according to the parental origin of 
inheritance (102). It is unclear why only certain genes are imprinted and rendered inactive 
during oogenesis or spermatogenesis but one of the mechanisms of this marking is by DNA 
methylation. Therefore the expression of imprinted genes is monoallelic. There are about 80 
imprinted genes in human and mice (103) and about 154 more are predicted to be imprinted 
(104). The first evidence of imprinting was from mice studies where mice created from 
nuclear material from either parent failed to survive after implantation (105). The imprinted 
genes are generally seen in clusters called Imprinting Control Region (ICR) or Differentially 
Methylated Region (DMR) (106). When there are multiple DMRs as seen in some genes like 
IGF2/H19 locus at chromosome 11p15.5 (107) then DMRs are classified into primary and 
secondary DMRs. The primary DMRs are conserved through the tissues while the secondary 
DMRs are variable (108). The ICR is CpG rich and is methylated on one of the two parental 
alleles. This monoallelic silencing is acquired at gametogenesis and is maintained postnatally 
in adult life imposing an epigenetic memory to ICR (109). Several  hypotheses have been put 
forward to explain why imprinting occurs, for e.g. a defence mechanism by the host against 
foreign DNA (110) or a method against parthenogenesis (111) or perhaps protection against 
invasive tumours like GTD (112). But the most accepted theory is called the ―parental 
conflict hypothesis‖(113). This hypothesis is based on the premise that paternal genes 
promote fetal growth while maternal genes restrict fetal growth. Since the role of placenta is 
to divert nutrients to the fetus and most imprinted placental genes are monoallelically 
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expressed this theory is most accepted (114). Several well known syndromes affecting 
growth due to imprinting defects include Silver-Russell syndrome (115), Beckwith-
Wiedemann syndrome (116) and Prader-Willi syndrome (117). Only a few imprinted genes 
are known until now and about 150 imprinted genes are yet to be identified (102) which will 
significantly help to understand more fetal pathologies we currently know little about. 
 
1.5.3. Histone modification   
 
Histones are highly alkaline nuclear proteins which form the chief component of chromatin 
acting as a spindle around which the DNA winds. This forms a basic unit of DNA called 
nucleosome. The nucleosome core consists of 147 base pairs of DNA wrapped around 2 
copies each of the core histones H2A, H2B, H3 and H4 (118). Histones are subject to post-
translational modifications at their amino acid terminal. These modifications include 
methylation, citrullination, acetylation, phosphorylation and ubiquitination, all of which 
affect gene regulation. In general, histones can have activating or a repressing effect and in 
some cases they co-exist, typically in the embryonic stem cells (119). Other histone functions 
are marking DNA damage sites (120), chromosome condensation (121) and spermatogenesis 
(122). 
 
1.5.4. MicroRNA   
 
MicroRNA (miRNA) are special non-coding single stranded RNAs that control gene 
expression by silencing and also by post-transcriptional regulation of gene expression (123). 
The miRNA is a part of RNA silencing complex called RISC (RNA induced silencing 
complex). The RISC can identify a complementary RNA strand, degrade it, thus affecting 
translation and switch off gene expression (124,125). miRNAs are also known to affect gene 
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regulation by histone modifications (126) and are also receptive to environmental changes 
(127). More than 450 human miRNAs are known  
(http:// microrna.sanger.ac.uk/sequences/index.html) and they are catalogued in a database 
http://www.mirbase.org (128). 
 
1.6. Drugs and Epigenetics   
 
Animal studies have shown that diet (129,130), drugs (131,132) and in vitro fertilisation 
(133) can mediate epigenetic changes. Animal models have been an important source of 
information especially since some rodents reach maturity within 2 months and have similar 
placentation to humans, thus making them ideal models to demonstrate a cause and effect 
relationship between environmental alterations, epigenetic changes and disease risk. Drugs 
such as opiates, amphetamines and nicotine can also modify the epigenome (134,135).  
Guinea pigs treated with glucocorticoids resulted in global methylation and expression 
changes in genes involved in epigenetic regulation (136). DNA methylation is also known to 
be under the influence of various dietary factors such as folate and vitamins which are 
important in mediating on-carbon metabolism and thereby affecting the availability of S-
adenosylmethionine (SAM) which is a co-substrate involved in methyl group transfers (137). 
Therefore, nutrition plays an important role in DNA methylation as also shown by Park et al, 
that folate levels affect DNA methylation in pregnancy (138). Growth restricted placentae 
have been shown to have increased folate transport as compared to normal placentae, 
interpreted as a compensator of weakness by the growth restricted placenta (139). There is 
further evidence showing distinct methylation patterns in genes involved in autism in 
offsprings of mice fed with low folate diet (140). Smoking is also known to alter DNA 
methylation and modify gene expression (141). Paternal factors are equally important in 
regulating environmentally induced epigenetic changes (142). Recent evidence suggests that 
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IGF2 hypomethylation in umbilical cord blood is linked to paternal obesity (143). These 
studies underline the importance of effects of the environment and drugs on epigenetic fetal 
programming.  
 
1.7. Epigenetic alterations and fetal growth disorders  
 
The intrauterine environment is critical in fetal programming (7) and the placenta plays an 
important role of assimilating, incorporating and optimising these effects to  further feto-
placental growth. Although studies linking epigenetic alterations and feto-placental growth 
are limited, there is still enough data to suggest a role of epigenetic mechanisms like DNA 
methylation in fetal growth restriction (13). Animal studies have shown that deletions of 
maternally expressed genes like GRB10, and Phlda2 causes placental overgrowth while 
deletions of paternally expressed genes like IGF2 and MEST results in a small placenta 
(91,144,145). Furthermore, mice studies have also shown that mutation of the enzyme, 
DNMT1 which maintains methylation disrupts imprinting (158). Animal studies have been 
supported by various human studies. A recent methylation bead chip array done by Banister 
et al (146) on 206 human term placentae has shown 22 differentially methylated loci which 
could prove to be useful markers to predict small for gestational age (SGA) and intrauterine 
growth retarded (IUGR) fetuses. Glucocorticoid receptor gene has been shown to be 
differentially methylated in growth restricted and macrosomic babies (147). A recent study 
has found an association between methylation of repetitive elements and fetal growth (148). 
Repetitive elements are parts of nucleic acids which occur in multiple copies in the genome, 
examples are Long or Short Interspersed Nuclear Elements (LINE or SINE) (149).  In 
summary the findings indicate that the DNA methylation profile is different in pregnancies 
with small or macrosomic fetuses compared to pregnancies with normal size babies.  
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1.8. Epigenetic alterations and gestational diabetes mellitus 
 
The placenta is known to produce diabetogenic hormones in pregnancy like oestrogen and 
prolactin which are known to divert nutrients and glucose to the fetus while the pancreatic 
islets in the mother counteract by increasing the production of insulin. However when the 
amount of maternal insulin produced becomes inadequate to match the increasing glucose 
levels, fetal insulin levels rise (150). The offsprings of diabetic mothers are known to be at 
risk of obesity (151), type 2 DM (152,153) , metabolic disease cardiovascular complications 
(154,155), and cancer (156). These findings further strengthen the Barker and Developmental 
Origins of Health and Diseases hypothesis (4,7) which noted the association between fetal 
growth disorders and development of metabolic disease in adult life. Alterations in epigenetic 
mechanisms due to hyperinsulinemia and hyperglycemia have been proven by tissue culture 
experiments (157,158). Cell culture studies have shown that hyperglycemia induced changes 
in histone acetylation by the citrate lyase pathway (158). Epigenetic changes have been 
observed in insulin receptor genes in overfed rats where the authors observed that the degree 
of methylation was directly proportional to the glucose levels (159). Human studies have also 
shown altered DNA methylation in GDM. A study observed reduced global methylation  
levels in placenta of women with GDM (160). Two recent microarrays have shown 
differential methylation in the placenta and cord blood of women with GDM as compared to 
normal controls with potential consequences on fetal growth and development (161,162). 
Thus, there is evidence that the diabetic intrauterine environment can epigenetically 
predispose the offspring to diseases in later life. 
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1.9. GRB10 and fetal growth regulation   
 
The cloning of human and mice GRB10 was done in 1995 (163,164). Human GRB10 is 
mapped to 7p11.2–p12 (165) and it belongs to a family of adaptor proteins which also include 
GRB7 and GRB14 (166). They are called adaptor proteins due to the presence of numerous 
protein binding motifs which can adapt and mediate interactions between discordant proteins 
(167). In vitro studies have shown the binding of GRB10 to tyrosine kinase receptors such as 
insulin receptor (INSR), IGF1 receptor (IGF1R) and epidermal growth factor receptor 
(EGFR) (163,164,167). GRB10 is imprinted and maternally expressed in humans, and is 
expected to limit growth as shown in mice studies (167). The SH2 domain of GRB10 had 
been shown to bind to tyrosine kinase receptors and inhibit the signalling pathway and all the 
downstream events (163). Studies in men have also shown GRB10 to be a negative regulator 
of insulin signalling and GRB10 knockdown resulted in reduction of insulin secretion likely 
contributing to the pathogenesis of type 2 diabetes mellitus (168). Genomic imprinting of 
GRB10 has been thought to be the consequence of increased DNA methylation as reported by 
various studies on pancreatic islets showing highest DNA methylation with reduced GRB10 
expression (169,170).  
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1.10. Hypothesis  
 
1) Placental gene expression and DNA methylation of the IGF system related genes and 
GRB10 is altered in pregnancies complicated by fetal growth disorders (pregnancies 
with small or large fetuses) and in those complicated by gestational diabetes mellitus 
(GDM) or increased body mass index (BMI). 
 
2) Umbilical cord levels of the IGF system related proteins are altered in women with 
fetal growth disorders and those affected by GDM and increased BMI. 
 
 
1.11. Aims 
 
1) To determine the expression levels and methylation status of the IGF system related 
genes and GRB10 in pregnancies with normal, small or macrosomic fetuses and in 
pregnancies complicated by GDM or increased BMI. 
 
2) To assess whether neonates of the above groups have altered IGF, IGFBP and 
GRB10 levels as measured in the umbilical cord blood. 
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2. Materials and Methods 
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2.1. Materials  
 
2.1.1. Chemicals and solvents 
 
                                                  
 
Acrylamide  Sigma-Aldrich  
 
Agarose  Invitrogen  
 
SYBR safe DNA gel stain  Invitrogen  
 
Ammonium Persulphate (APS)  VWR  
 
β-Mercaptoethanol  Sigma-Aldrich  
 
Bovine serum albumin (BSA)  Sigma-Aldrich  
 
Bromophenol Blue  Bio-Rad  
 
Dimethyl Sulfoxide (DMSO)  Sigma-Aldrich  
 
Dithiothreitol (DTT)  Bio-rad  
 
Glycerol  BDH  
 
HEPES  Sigma-Aldrich  
 
Isopropanol  Fisher Scientific  
 
Methanol  VWR 
 
Non-fat dried milk powder  Applichem  
 
TEMED  Sigma-Aldrich  
 
Triton X-100  Sigma-Aldrich  
 
Tween 20  Sigma-Aldrich  
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2.1.2. Reagents and Buffers 
 
General buffers  
 
 
 
 
Phosphate Buffered Saline (PBS)  
 
 
 
 
 
140mM NaCl  
 
2.5mM KCl  
 
1.5mM KH2PO4  
 
10mM Na2HPO4  
 
pH 7.2  
 
 
 
Tris Buffered Saline (TBS)  50mM Tris-HCl  
 
150mM NaCl  
 
pH 7.5  
 
 
 
Tris-EDTA (TE) Buffer  10mM Tris-HCl  
 
1mM EDTA  
 
pH 8.0  
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RIPA whole-cell protein extraction buffer  1% (v/v) Triton X-100  
 
1% (w/v) Sodium deoxycholate  
 
0.1% (v/v) SDS  
 
150mM NaCl  
 
10mM Tris, pH 7.4  
 
1mM EDTA  
 
1mM PMSF  
 
Protease and phosphatase inhibitor cocktail  
 
 
 
Western Blotting reagents and buffers  
 
 
Pre-stained protein markers  
 
 
 
Fermentas  
 
PVDF membrane  Millipore  
 
ECL Plus Western blotting reagent  Fisher Scientific  
 
ECL Western blotting reagent  Fisher Scientific  
 
Supersignal Western blotting reagent  Fisher Scientific  
 
ECL plus hyper film  Amersham Biosciences  
 
Whatman 3MM paper  Bio-Rad  
 
30% Acrylamide/Bis  Sigma-Aldrich  
 
Tris-Glycine running buffer  25mM Tris-base  
 
250mM glycine  
 
0.1% (w/v) SDS  
 
pH 8.3  
 
Transfer Buffer (TB)  39mM glycine  
 
48mM Tris-base  
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20% (v/v) methanol  
 
Blocking Buffer  0.01% (v/v) Tween-20  
5% (w/v) non-fat milk   
 
                                                                            in TBS-T  
 
Washing Buffer (TBS-T)  0.01% (v/v) Tween-20  
 
in TBS  
 
 
 
Pyrosequencing reagents and buffer 
 
Sepharose high performance beads                      GE Healthcare  
 
Pyromark binding buffer                                      Qiagen 
 
Pyromark Q96 Vacuum Workstation                    Qiagen 
 
Pyromark wash buffer                                           Qiagen 
 
Pyromark annealing buffer                                    Qiagen 
 
0% and 100% methylated DNA                             Millipore, Cat no - S7821 
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2.1.3. Kits  
 
 
 
RNeasy Mini Kit                                          
 
 
 
Protein assay Kit  
 
 
 
 
 
        Qiagen 
 
 
 
         Bio-Rad  
 
  
First strand cDNA synthesis           Sigma-Aldrich  
 
 
SYBR Green master mix           Sigma-Aldrich  
 
 
QIAquick PCR purification Kit  
 
 
Faststart Taq DNA polymerase Kit                                                  
         Qiagen  
 
 
         Roche
 
 
Purelink Genomic DNA extraction Kit            Invitrogen  
 
EZ DNA methylation Gold Kit             Zymo Research, Irvine, CA, USA 
              
Quantibody
® 
Human Signalling Array 1 kit              Raybiotech, QAH-IGF-1 
(Multiplex ELISA)                               
      
GRB10 ELISA Kit                                                    Elabsciences, E-EL-H1925.                                               
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2.2. Methods 
 
We obtained placental biopsies, following delivery, from women that delivered normal size 
neonates (n = 37), small for gestational age (SGA) neonates (n = 16), defined as birthweight 
<10
th
 percentile for gestation, adjusted for gestational age, and large for gestational age (LGA) 
neonates (n = 20), defined as birthweight ≥ 90th percentile for gestation, adjusted for gestational 
age. This cohort was used for studying the placental genetic and epigenetic changes in the IGF 
system related genes and GRB10 in women with fetal growth disorders as described in Chapter 
3. We also collected placental biopsies from women with increased body mass index (BMI > 30) 
with normal sized neonates (n =14) and from another group of women affected with gestational 
diabetes mellitus (GDM) as diagnosed at 28 weeks gestation by an oral glucose tolerance test 
(OGTT). This cohort is described in Chapter 4 and the GDM group included women on diet only 
treatment (n = 23), women on diet and metformin treatment (n = 23) and women on diet and 
insulin treatment (n = 14). Placental samples were collected from the fetal side near cord 
insertion immediately after delivery and washed with PBS to remove contaminants. Areas which 
appeared calcified or necrosed were excluded and samples were stored in a -80°C freezer until 
further analysis. Umbilical cord tissue, amniotic membranes and decidua were also excluded. 
We analysed umbilical levels of the IGF system related proteins from normal controls, SGA and 
LGA neonates and from pregnancies affected by GDM. Umbilical levels of GRB10 was 
analysed in normal, SGA and LGA neonates. The umbilical samples were from the same cohort 
which was investigated for epigenetic and gene expression studies in their respective subgroups. 
All the pregnancies were dated by a first trimester scan at 11-13 weeks of gestation. Booking 
maternal body mass index (BMI) was calculated as weight/height in kg/m
2
. All patients gave a 
signed informed consent form and the study had approval by the local London – Central REC 
(REC no 11/LO/1315).  
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2.2.1. Maternal and neonatal characteristics for women with fetal growth disorders 
 
Variables Controls  
(n = 37) 
Small for gestational 
age 
(n = 16) 
Large for 
gestational age 
(n = 20) 
P value  
(overall) 
Maternal age (yrs) 31.5 (28.7-35.0) 31.5 (25.2-33.7) 33.0 (30.0-37.2) 0.173 
Parity, n (%)     
Nulliparous, n (%) 20 (52.6) 10 (62.5) 11 (55.0) 0.8 
Parous, n (%) 18 (47.4) 6 (37.5) 9 (45.0)  
Racial origin     
Caucasian, n (%) 25 (65.8) 11 (68.8) 19 (95.0) 0.07 
Black, n (%) 7 (18.4) 3 (18.8) 1 (5.0)  
Other, (%) 6 (15.8) 2 (12.4) 0 (0)  
Smokers, n (%) 1 (2.6) 2 (12.5) 1 (5) 0.341 
Maternal body 
mass index at 
booking 
23.0 (20.0-25.2) 22.0 (20.2-24.0) 24.5 (23.2-27.0) 0.09 
Gestational age at 
delivery (wks) 
39.2 (39.0-41.0) 36.5 (32.2-38.8)* 39.5 (39.0-40.0) 0.001 
Birthweight 
percentile 
54.5 (21.0-76.2) 1.4 (0.3-6.8)* 98.3 (95.2-99.6)* <0.001 
 
Table 2.1 Maternal and neonatal characteristics for women with fetal growth disorders 
Data are expressed as mean ±SEM or as median (interquartile range). Comparisons between categorical and 
continuous variables were done by x
2
 or Fisher’s exact test and Mann-Whitney test both with post hoc Bonferroni 
correction. *p<0.05= significant vs. normal controls. 
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2.2.2. Maternal and neonatal characteristics for the women with gestational diabetes and non-
diabetic women with raised BMI 
 
 
 
Characteristics 
 
Controls 
(n = 37) 
 
GDM on 
diet 
(n = 23) 
 
GDM on 
metformin 
(n = 23) 
 
GDM on 
insulin 
(n = 14) 
 
Raised BMI 
(n = 14) 
 
P value 
(overall) 
 
Maternal age (yrs) 
 
31.7±4.5 
 
34.2±6.2 
 
33.3±7.1 
 
35.5±5.1 29.2±1.9 
 
0.14 
 
BMI at booking (kg/m2) 
 
23.0 ± 3.5 
 
25.0 ±5.2 
 
27.0 ±4.7 
 
29.1±6 40.5±1.3 
 
0.07 
Race                                                
White (N, %)                
Black (N, %)                       
Other (N, %) 
22 (59.4) 
6 (16.2) 
9 (24.3) 
 
14 (60.8) 
7 (30.4) 
2 (8.6) 
 
11 (47.8) 
6 (26) 
6 (26) 
 
10(66.6) 
3(20) 
2(13.3) 
 
8(57.1) 
6(42.9) 
0(0) 
0.31 
Parity                       
Nulliparous (N, 
%)Multiparous (N, %) 
 
22 (59.5) 
15 (40.5) 
 
9 (39.1) 
14 (60.8) 
 
8 (34.7) 
15 (65.2) 
 
6(40) 
8(60) 
 
6(40) 
8(60) 0.17 
Smoking                                               
Yes (N, %)                                
No (N, %) 
 
1 (2.7) 
36 (97.3) 
 
3 (13) 
20 (87) 
 
3 (13) 
20 (87) 
 
2(14.2) 
12(85.8) 
1(7.2) 
13(92.8) 
0.42 
Gestational age at 
delivery (weeks) 39.5 (39-41) 
38.4 (37.6-
39.1) 
39.1 (39-40) 
37.2 (37 – 
38.1) 
39.3(38.2 -
39.5) 
0.10 
 
Birthweight percentile 
 
58.7 ± 3.4 
 
52.0 ± 6.8 
 
50.35 ± 6 
 
69.21± 8 30.7±5.7 0.13 
 
Table 2.2 Maternal and neonatal characteristics for women with GDM and raised BMI 
Data are expressed as mean ±SEM or as median (interquartile range). Comparisons between categorical and 
continuous variables were done by x
2
 or Fisher’s exact test and Mann-Whitney test both with post hoc Bonferroni 
correction. *p<0.05= significant vs. normal controls. 
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2.3. RNA extraction  
 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Germany) according to 
manufacturer’s instructions. 30mg of frozen tissue was homogenised in the 600µl of Lysate 
Buffer at room temperature. The buffer is known to dissolve cellular components whilst 
maintaining the stability of RNA during homogenisation. The lysate was centrifuged at full speed 
for 3 minutes. The supernatant was carefully pipetted out into a new microcentrifuge tube and 
350µl of 70% ethanol added and mixed to the lysate by pipetting. 700µl of the sample was 
transferred to a RNeasy spin column in a 2ml collection tube and centrifuged for 15 seconds at 
8000 x g (>10000 RPM) and follow through discarded. 700µl of Buffer RW1 was added to the 
spin column and centrifuged for 15 seconds at 8000 x g and follow through discarded. 500µl of 
Buffer RPE was added to the column and centrifuged for 15 seconds at 8000 x g discarding the 
follow through. 500µl of Buffer RPE was added again to the column and centrifuged for 2 
minutes at 8000 g to wash the spin column membrane. The RNeasy spin column was then placed 
in a new microcentrifuge tube and centrifuged at full speed for 1 minute to remove any residual 
buffer. The spin column was then placed in a new collection tube and 30µl of RNase – free water 
was added to the spin column membrane and centrifuged at 8000 x g for 1 minute to elute the 
RNA. The quantification was performed by Absorbance (OD A260nm) on the Nanodrop 
ND1000 instrument (Thermo Scientific) and the A260/A280nm ratio (>2.0) was also determined 
to ensure a high quality sample. To avoid repeated freezing and thawing the aliquots of RNA 
were stored at -80°C till further use. 
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2.4. DNase treatment and first-strand cDNA synthesis 
 
Any contaminating DNA was removed by DNaseI (Sigma) reaction buffer treatment room 
temperature for 15 minutes and cDNA prepared by using the MMLV kit (Sigma®, Cat No 
M1302) according to manufacturer’s instructions by reverse transcription of 1µg of total RNA. 
Once the DNaseI digestion is complete, the reaction was stopped by incubating at 70°C for 10 
minutes with 1μl of 25mM EDTA, and the whole reaction was used for first-strand cDNA 
synthesis. The DNaseI treated RNA was incubated at 70°C for 10 minutes 1µl of 10mM dNTP 
mix (10mM of dATP, dTTP, dGTP and dCTP each), 1μl Oligo(dT)12-18 (0.5μg/μl), then 
incubated in ice for 1 minute. Subsequently the following components were added 2µl of 10 x 
M-MLV Reverse Transcriptase Buffer, 1 µl of M-MLV Reverse Transcriptase, 0.5µl of RNAse 
Inhibitor (40units/µl) and 6.5ul of Nuclease-free water to make a total volume of 20µl. The 
reaction tube was then incubated at 90°C 10 minutes to denature the M-MLV reverse 
transcriptase. The cDNA strand was then stored at -20°C till further use.  
 
2.5. Real-time PCR 
 
Real time quantitative polymerase chain reaction (RT-PCR) was carried out using ABI StepOne 
Real Time PCR system (Applied Biosystems) for quantification of target cDNA. Real-time PCR 
was initially used to optimise the respective primers. SYBR Green I dye which was used for the 
RTQ-PCR generates fluorescence after incorporation into the double-stranded DNA. Therefore 
an increase in the accumulation of PCR product leads to higher emission of SYBR Green 
fluorescence and this is detected by the Real Time PCR system throughout the cycle. Specific 
primers were used (Table 2.3) to carry out amplification of the target DNA. The fluorescence 
baseline was determined by the software which then generates a baseline-subtracted 
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amplification plot by calculating a mathematical trend of the normalized fluorescent reporter 
signal. The Ct value is defined as the cycle number at the point of amplification plot where it 
crosses the threshold and it is used as a quantitative measurement of the input target. A decrease 
in the Ct value is seen as an increase in the target cDNA. The target Ct values were normalised to 
L19 for analysis. 2 µl of cDNA was added to 8µl of reaction mix to make a total of 10 µl per 
well. The reaction mix consisted of 5 µl of SYBR Green (Sigma®, Cat No QR0100), 0.2 µl of 
ROX Reference Dye (Sigma®, Cat No R4526), 300nM of each primer, and RNase free water to 
make up the remaining volume. The steps of the quantification PCR included initial denaturation 
at 94°C for 2 min following which samples were subjected to 40 amplification cycles comprising 
of denaturation at 95°C for 15 sec, annealing and elongation of each gene for 60 sec. All the 
mRNA data was expressed as a relative quantification to the total amount of similarly expressed 
L19 gene.  
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Gene Forward primer Reverse Primer 
IGF1 CAGCAGTCTTCCAACCCAT ACAGCGCCAGGTAGAAGAG 
IGF2 CAATATGACACCACCGTGCT GGACTGCTTCCAGGTGTCAT 
IGFBP1 CTGCCAAACTGCAACAAGAA GAGACCCAGGGATCCTCTTC 
IGFBP2 ATGGCGATGACCATCAGA ACCTGGTCCAGTTCCTGTTG 
IGFBP3 CAGAGACTCGAGCACAGCAC GCCGCCTAAGTCACAAAGTC 
IGFBP4 CCCACGAGGACCTCTACATC ATCCAGAGCTGGGTGACACT 
IGFBP5 AGCAGCAACGTTGAGTGATG GATGAAATGAGTGGCGTCCT 
IGFBP5 
GGGCTCCTTCGTGCACTG TCCTTGACCAGCTCGCAG 
IGFBP6 GCTGTTGCAGAGGAGAATCC GGTAGAAGCCTCGATGGTCA 
IGFBP6 GCGTGGAGGAGGAGGATG GTAGACCCCGCACTCCTG 
IGFBP7 CATCCAATTCCCAAGGACAG TATAGCTCGGCACCTTCACC 
GRB10 TCCCTGGAGAGCCTGTACTC GCTGGATGGACCGAGGAG 
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 
              
             Table 2.3 Sequences of PCR primers used in RT-PCR 
 
2.6. DNA purification  
The respective primers (Table 2.3) were optimised by RT-PCR and the PCR products in the 
wells showing the lowest Ct value were cleaned and purified using the QIAquick PCR 
Purification Kit (Qiagen) according to manufacturer’s protocol. One volume of the RT-PCR 
product and five volumes of Buffer PB were placed into a QIAquick spin column. The 
columns were centrifuged for 1 minute at 17,900 x g to bind DNA. The columns were washed 
with 0.75ml of Buffer PE and centrifuged for another minute. The follow through was 
discarded and to remove any residual ethanol from Buffer PE centrifugation was performed 
for an additional minute at maximum speed and the columns were kept in a clean 
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microcentrifuge tube. The purified DNA was eluted by adding 50μl of Buffer EB, or RNase-
free water to the centre of the QIAquick membrane and again centrifuging for 1 minute. 
Serial dilutions from the purified DNA in the ratio of 1:10 were made which were then used 
in duplicate in the real time PCR reactions to generate a standard curve for the respective 
gene. 
 
2.7. Protein extraction, western blot and immunodetection 
 
Placental samples were homogenised in modified RIPA buffer containing 1% Triton x 100, 
1% Sodium Deoxycholate, 0.1% SDS, 150mM Sodium Chloride, 10mM Tris (pH 7.4) and 
1mM EDTA with 1mM of PMSF and protease inhibitor cocktail (Sigma-Aldrich) which was 
used to lyse the placental samples. The lysate was centrifuged at 13,000xg for 30 minutes at 
4°C and the whole cell protein was obtained by extracting the supernatant. Lowry method 
(Bio-Rad) was used for quantification of protein extracts. Aliquots of protein samples were 
stored at -80°C to avoid freeze-thaw cycles. Protein denaturation was performed at 80°C for 
10 minutes with loading dye consisting of 3% glycerol, 3% SDS, 1% Bromophenol Blue, and 
β-mercaptoethanol. Equal amount of proteins (50μg) were run either on a 10% SDS-
Polyacrylamide gel for 80 minutes at 120V, and were transferred to polyvinylidene difluoride 
(PVDF) membranes (Millipore) for 90 minutes at 300mA or on a Biorad Criterion TGX Gel, 
26-well midi gel (Cat No 567-1085) for 80 minutes at 120V and transferred for 7 minutes on 
a Tran-Blot® Turbo™ Midi PVDF Transfer Pack (Cat No 170-4157). Membranes were 
incubated in 5% blocking buffer for 1 hour at room temperature and subsequently incubated 
with the primary antibody overnight at 4°C. Incubation with secondary antibody was then 
carried out the following day and immunodetection using ECL2 or ECL (Fisher Scientific). 
The primary antibodies used were: 
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Primary Antibody Catalogue number Supplier 
IGF1 Ab9572 Abcam 
IGFBP1 Sc-55474 Santacruz 
IGFBP2 Ab109284 Abcam 
IGFBP3 Sc-6004 Santacruz 
IGFBP4 Sc-6005 Santacruz 
IGFBP7 Sc-13095 Santacruz 
GRB10 3702 
Cell Signalling 
Technology 
β-actin Ab6276 Abcam 
Liver (Human) Tissue 
Lysate 
Ab29889 Abcam 
 
Table 2.4 Details of primary antibodies and controls used in Western immunoblotting 
 
2.8. Gene promoter assays  
The CpG assays were designed using the Pyromark CpG software (Qiagen) and the genomic 
sequences were extracted from the USCS genome browser at www.genome.uscs.edu (171). The 
CpGs were identified from the promoter region of each of the target gene. The promoter regions 
were identified from sequences up to 500bp upstream of the transcription start sites (TSS) (Table 
2.4). To address epigenetic events associated with fetal growth disorders we analysed CpG 
methylation at 3 sites in the IGF1, IGFBP1 and IGFBP2 promoter regions, 5 sites in IGFBP3 
and IGFBP7 and 7 sites in the IGFBP4 promoter regions for the cohort of fetal growth disorders 
(Figures 3.9 to 3.14, A) and an additional 2 CpGs in the IGFBP1 promoter (Figure 4.5) for the 
GDM cohort.   
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2.9. DNA extraction 
 
Purelink Genomic DNA Extraction Kit (Invitrogen, K1820-02) was used for extracting DNA. 
Heat block was set at 55C and 25mg of placental tissue was incubated in 180µl of Purelink 
Genomic Digestion Buffer and 20µl of Proteinase K. The tissue was completely immersed in the 
buffer mix and incubated at 55C with occasional vortexing until lysis was complete (1-4 hours). 
The lysate was centrifuged at full speed for 3 minutes at room temperature to remove any 
particulate matter. The supernatant was transferred to a new sterile microcentrifuge tube; 20µl of 
RNase A was added to the lysate and incubated at room temperature for 2 minutes. Subsequently 
200µl of Purelink Genomic Lysis Buffer was added to the lysate and vortex mixed. Absolute 
ethanol 200µl was added to the lysate and vortexed for 5 seconds. Approximately 640µl of the 
lysate was then added to the Pure Link Spin column and centrifuged at 10,000xg for 1 minute. 
The spin column was then washed with 500µl of Wash Buffer 1 at 10,000xg for 1 minute the 
follow through discarded and washed again with Wash Buffer 2 at full speed for 3 minutes and 
the collection tube discarded. The DNA was then eluted by adding 25µl of Pure Link Genomic 
Elution Buffer, incubating at room temperature for 1 minute. The quantification was performed 
by Absorbance (OD A260nm) on the Nanodrop ND1000 instrument (Thermo Scientific) and the 
A260/A280nm ratio (>1.8) was also determined to ensure a high quality sample. To avoid 
repeated freezing and thawing the aliquots of DNA were stored at -20°C till further use. 
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2.10. Bisulphite modification  
 
EZ DNA Methylation Gold TM Kit (Zymo Research, Irvine, CA, USA) was used for sodium 
bisulphite conversion. This process replaces unmethylated cytosine residues with uracil while 
methylated cytosines remain unchanged. The uracil gest converted to thiamine by PCR and thus 
a stable product is generated which can then be sequenced. Genomic DNA (500ng) was added to 
the CT conversion agent, mixed by pipetting and incubated at 98°C for 10 min and 64°C for 2 h 
and 30 min. The sample was then added to a Zymo-spin column containing 600ul of M-binding 
buffer and centrifuged at full speed for 30sec. The follow through was discarded and 100µl of 
M-wash buffer added to the column and centrifuged for 30 seconds. 200µl of M-desulphonation 
buffer was then added to the column, and incubated at room temperature for 20 minutes. This 
was followed by centrifugation for 30 seconds and two rounds of washing and centrifugation 
with 200µl of M-wash buffer for 30 seconds. The column was then eluted with 10µl of M-
elution buffer in new microcentrifuge tube, centrifuged for 30 seconds and the bisulphite 
converted DNA stored at -20°C until further use.  
 
2.11. Polymerase Chain reaction   
 
The forward and reverse primers (Table 2.5) were reconstituted with DNAse free water to 
acquire concentrations of 150ng/µl and sequencing primer of 10µmol. Polymerase chain 
reactions (PCR) were performed using Fast Start Taq DNA polymerase (Roche-Applied-
Science, Cat no. 12032929001). The following protocol was used to make the PCR reaction 
mix. Each reaction included 0.9μl of dNTP mix, 4.5μl PCR reaction buffer with 3.2μl MgCl2, 
1μl each of forward and reverse primers, 0.45µl of FastStart Taq DNA Polymerase, 2µl 
(500ng) of bisulphite treated DNA and 29.45μl of water to make a total volume of 45µl. DNA 
57 
 
amplification in a thermocycler was performed by following these PCR conditions: one cycle 
at 95°C for 6 min, followed by 40 cycles of 95°C for 30 s, annealing temperature of 55°C to 
59°C (depending on primer pair) for 30s and 72°C for 30s, followed by one cycle at 72°C for 
30s. Following this the PCR products were analysed by agarose gel electrophoresis to ensure 
correct product size and lack of contamination. 
 
 
Gene Primer Sequence 
IGF1 
Forward GATAGGAAATAGTTGGGGGAATATTTGT 
Reverse AATCTACTTTACCCCAATCACTTCAA 
Sequencing 1 AAAGAATGTGTGTTAGTG 
Sequence to 
analyse 1 
ATAGGGTTYGTAGAT 
Sequencing 2 ATTTTTTGTTGGGTATGAAG 
Sequence to 
analyse 2 
ATATAAAYGTTTGTTAATAT 
Sequencing 3 GTAAATGTATTATTTAAAATAAAAA 
Sequence to 
analyse 3 
AAGAAAGAAAGGAYGATAAGATT 
IGFBP1 
Forward TTGAGTAGGGTTTTGGGTGTATTAGTAA 
Reverse AACCCAAACTCTAAACAAATAATAAT 
Sequencing AAATTTATTTTGAATATTTAGTTTT 
Sequence to 
analyse 
TAGYGTGYGGYGTTGTTAATTATTAATTTT TTGGTGTAAGTGGYGYGGT 
IGFBP2 
Forward TGGGGGTTTAGGGTGTTAAG 
Reverse CTAACCCCTAAAAAACACAAAAAACAT 
Sequencing TTAGGGTGAAAGGGAT 
Sequence to 
analyse 
TTGGTTTAGAYGGGTTTGAAATTTYGTAGG 
ATTTATTTAATAAGAAGTTATTGTTTTAAGTTAYGTGT 
IGFBP3 
Forward AGAAGTAGGGGTGGTTTAGGATA 
Reverse AAACCCTATATACCAATTTCCC 
Sequencing AGGAGTGGGGGTTTGGGAGGGGG 
Sequence to 
analyse 
GYGGGTYGGYGTAGGTAYGGTTGYGGGGGTTYGTG 
IGFBP4 
Forward GGGGTTTAGGTTTAGAGGTATTTTGG 
Reverse ACCCCCAACCCCTTCCCAAAAAT 
Sequencing TTTTTAGGTAGAAAAGGATTTTTA 
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Sequence to 
analyse 
GYGGYGGYGGYGGYGGYGATTTAGGATAGYGT 
IGFBP7 
Forward GGAAAGGGGAGAAATTAGAGGG 
Reverse TCCTACTCCATCCCCAAT 
Sequencing GAGAAATTAGAGGGTGG 
Sequence to 
analyse 
AAGAGTYGTTYGTATTGYGGTGYGATTTTTGAGGGTTYGG 
GRB10 
Forward GTTGAGTTTAGGATAAAGGATTTGGAT 
Reverse ATTCCCCCCTCCTACTAT 
Sequencing AGGATAAAGGATTGGATT 
Sequence to 
analyse 
GYGTAGTTAATATTGTGYGTTTTAAATAGTTYGTTTATAAATTGTTTTTY 
 
Table 2.5 Details of primers used for PCR and pyrosequencing 
 
2.12. Agarose Gel Run 
 
Agarose gels 1.5% (w/v) was used to analyse the final PCR products. Agarose was dissolved 
in 1x TBE followed by heating until the agarose mixed into the solution. This was followed 
by cooling of the solution at which point SYBR safe (Invitrogen) was added prior to pouring 
the gel into a gel mould. Once the gel was set, it was submerged in 1 x TBE buffer. 5μl of the 
PCR product with 1μl of DNA loading dye (Promega) was then loaded into the wells. 
Electrophoresis was then carried out at 90V until the dye front reached the end of the gel. A 
100bp size DNA ladder (Bioline) was used to ensure correct fragment size. The bands were 
imaged using a dark reader (Dark Reader transilluminator, Clare Chemical Research). 
 
 
 
 
 
59 
 
2.13. DNA Pyrosequencing  
PyroMark Q96 ID (Qiagen) was used for pyrosequencing analysis. 10 μl of biotinylated DNA 
obtained with the PyroMark CpG Assays were complexed with 2μl Streptavidin Sepharose High 
Performance beads (GE Healthcare) in a solution containing 30 μl of water and 38 μl PyroMark 
Binding Buffer (Qiagen) per reaction. The pyrosequencing plate was prepared with 12ul of 
PyroMark Annealing Buffer (Qiagen) containing 0.3 µM of sequencing primer. After vortex 
mixing for 10 minutes at room temperature the PCR mixture was captured onto the filter probes 
of the PyroMark Q96 Vacuum Workstation Tool (Qiagen). The beads were washed with 70% 
ethanol, denatured in 0.2 M sodium hydroxide (NaOH) to ensure that only single stranded DNA 
remained attached to the beads. The beads were then further washed in PyroMark Wash Buffer 
(Qiagen) to remove any denaturing solution (NaOH) left and then released on the 
pyrosequencing plate. The plate was heated for 5 minutes at 80°C in a heating block and then 
allowed to cool for 2 minutes to allow annealing of the sequencing primer to the PCR product. 
The capillary tips were then loaded with correct volumes of the PyroMark Gold 96 reagents and 
the correct dispensation of the tips tested on an empty pyrosequencing plate. The 
pyrosequencing plate which contained the PCR product and the sequencing primer was then 
loaded on the pyrosequencer and run started. Assay efficiency was validated by an unmethylated 
control generated from whole genome amplification of cell line DNA with GenomiPhi V2 
amplification Kit (Life Sciences) and a 100% methylated control DNA (Millipore). The 
methylation data was analysed by Pyro Q-CpG software 1.0.6 and the programme calculates the 
ratio of unmethylated cytosines to methylated cytosines at each CpG site to quantify 
methylation. Transcription factor prediction at the promoters of the target genes was done by 
using the transcription factor binding site predictor tool, PROMO (version 3.0.2) 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3[54]. 
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2.14. Multiplex ELISA for IGF system related genes 
 
For the multiplex ELISA assays Quantibody
® 
Human Signalling Array 1 kit was used 
(Raybiotech, cat no. QAH-IGF-1) which detects IGF1, IGFBP1, IGFBP2, IGFBP3 and IGFBP4 
in human sera. Each glass slide had 16 wells of identical cytokine antibody arrays. Each 
antibody was analysed in duplicate and mean values taken. The fluorescence scanner used was 
Innopsys Innoscan 710 (Raybiotech). The glass slides were left to equilibrate at room 
temperature inside a sealed plastic bag for 20min and then outside the bag at room temperature 
for 2 hours to ensure complete drying. Standards were constituted from the lyophilised cytokine 
standard mix in a ratio of 1:100 from standard 1 to 7 excluding the control. 100µl of the sample 
diluent was added to each of the 16 wells of the slide and blocked for 30 minutes. After 
decanting 100µl of sample was added to each well and incubated at room temperature for 2 
hours. Each well was then washed according to instructions following which the wells were 
incubated with 80µl of the biotinylated antibody overnight at 4°C. The wells were then washed 
and 80µl of Cy3 equivalent dye-conjugated streptavidin was added to each well and incubated 
for 1 hour at room temperature in a dark room. The wells were then dried according to 
instructions and dried by gentle shaking at room temperature for 15 minutes before being 
analysed in the laser scanner (Innopsys Innoscan 710). 
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2.15. ELISA for GRB10 
 
GRB10 ELISA was performed using the kit from Elabsciences cat no. E-EL-H1925. All the 
reagents were used at room temperature. Wash buffer was constituted by diluting 30ml of 
concentrated Wash Buffer into 750ml of Wash Buffer with distilled water. Standard was 
prepared within 15 minutes before use. It was centrifuged at 10000 x g for 1 minute and 
reconstituted with 1ml of Reference Standard and Sample Diluent. The vial was let to stand for 
10 minutes and then turned upside down several times to mix it. This gave a stock solution of 
20ng/ml and serial dilutions were made as follows: 20, 10, 5, 2.5, 1.25, 0.63, 0.31, and 0 ng/ml.  
350µl wash buffer was used to wash the wells and dried by inverting the plate and blotting dry 
on absorbent paper. All the reagents were used at room temperature and mixed thoroughly by 
gentle swirling avoiding foaming. 100µl of standards and samples were added to each well. 
Blank well was added with Reference Standard and Sample Diluent. After mixing gently the 
plate was sealed and incubated for 90 minutes at 37°C. The liquid was removed from each well 
without washing and 100µl of Biotinylated Detection Antibody solution was added to each well, 
covered with plate sealer and incubated for 1 hour at 37°C. Each well was then aspirated and 
washed three times with 350µl of Wash Buffer and the plate was inverted and buffer removed by 
decanting against a clean absorbent paper. 100µl of HRP Conjugate working solution was added 
to each well and incubated at 37°C for 30 minutes. The wash procedure was then repeated five 
times. Following this 90µl of Substrate Solution was added to each well and the plate was sealed 
and incubated for 15 minutes at 37°C in dark. 50µl of Stop Solution was then added to each well 
and the colour change to yellow was noticed. The optical density OD value was immediately 
checked using a micro-plate reader at 450nm. 
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2.16. Statistical Analysis 
 
Kolmogorov-Smirnov test was used to determine normality of the data. Data were expressed as 
mean ±standard error of mean or as median (interquartile range). Comparison between groups 
for continuous variables was by Student’s t test, Mann Whitney U test, one way analysis of 
variance and Kruskal-Wallis test for normally and not normally distributed data.  Post-hoc 
Bonferroni correction was used for adjustment for multiple comparisons. Categorical data were 
compared using x
2
-test. Univariate analyses were used to investigate the association between 
birth weight percentiles and different variables. Statistical analysis was performed using 
Graphpad Prism 5.0 (Sandiego, CA, USA) and results were considered significant if p value was 
<0.05. 
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3.  Epigenetic, transcriptional and translational variation in placental IGFs 
and its binding proteins in fetal growth disorders 
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3.1. Introduction  
 
The insulin-like growth factors play a crucial role in promoting fetal and placental growth 
throughout gestation (172). The first link between IGF axis and fetal growth was from clinical 
studies where lower IGF umbilical venous levels were detected in small for gestational age 
(SGAs) and higher IGF levels were found in large for gestational age (LGA) neonates 
(44,173,174). Mice studies have shown that mutations in IGF1 and IGF2 resulted in 40% 
reduction in the weight of the offsprings (30) while IGF2 knockout mice had poor placental and 
fetal growth (29,30). It is known that the IGFBPs modulate the bioavailability of IGFs and can 
therefore regulate the IGF function; however animal studies have also shown an independent 
association between altered IGFBP levels and fetal growth. For example increased circulating 
IGFBP1 in mice was associated with poor fetal growth despite no changes in IGF1 levels (175). 
Human studies investigating placental and umbilical levels of IGFBPs in fetal growth disorders 
have been limited with no conclusive results and most studies describing IGFBP1, IGFBP2 and 
IGFBP3 (39,42,176,177) but not IGFBP4, IGFBP5, IGFBP6 and IGFBP7. We sought to 
investigate the placental expression of IGF1, IGF2 and their binding proteins in women with 
normal size neonates (n = 37) and those with SGA (n = 16) and LGA (n = 20) neonates. We also 
investigated the umbilical cord levels of proteins of those genes which were differentially 
expressed in our whole cohort (n = 15 each in normal controls, SGA and LGA neonates). All our 
placental samples were collected from the fetal side of the placenta around the umbilical cord 
insertion from women delivering at term, while all the cord blood samples were collected from 
the umbilical vein thus ensuring consistency unlike previous studies. 
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3.2. Placental IGF1 and IGF2 gene expression 
 
Studies in mice have shown that IGF1 knockout mice have reduced birth weight  (29). There is 
also similar evidence in humans, who are born small with IGF1 gene defects (178). 
Furthermore, IGF2 overexpression has been shown to be associated with fetal overgrowth, as 
found in Beckwith-Wiedemann syndrome (179). Placental IGF1 mRNA expression was found 
to be significantly lower in women with SGA neonates compared to controls (Figure 3.1, A). 
Western blot analysis of placentae from SGA fetuses (Figure 3.1, B) showed a trend towards 
decreased IGF1 protein content, although this was not statistically significant. The IGF1 protein 
content in LGA neonates was not analysed since the placental IGF1 mRNA expression in LGA 
was not significantly different as compared to normal controls. There was also no significant 
difference in IGF2 mRNA expression in SGA or LGA neonates compared to controls (Figure 
3.1, C).  
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Figure 3.1 Placental IGF1 and IGF2 gene expression. (A) Placental IGF1 mRNA expression in normal size 
(n = 37), SGA (n = 16) and LGA (n = 20) neonates,*p < 0.05; SGA vs. normal controls, Mann Whitney. 
(B) Representative western blot and densitometry analysis of IGF1 (8kDa) in SGA group (n = 16).  Control 
with β-actin (42kDa) to correct protein loading. (C) Placental IGF2 mRNA expression. 
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3.3. Placental IGFBP gene expression  
There are seven types of IGFBPs (17) which regulate IGF bioavailability. Apart from prolonging 
half-life and increasing the bioavailability of IGFs they serve other important functions such as 
prevention of IGF induced hypoglycaemia, transfer of IGFs from the intravascular to 
extravascular compartment and direct actions mediated by some of their own receptors (180). 
Therefore the IGFBPs are as important as the IGFs in regulating growth and glucose 
homeostasis. Also all the IGFBPs share at least 50% homology (181) and have been shown to 
have high affinity binding to the IGFs (17).  
 
3.3.1. Placental IGFBP1 gene expression 
The minute to minute availability of free IGF1 in the circulation is regulated by IGFBP1 which 
sequesters IGF1 (182). At term, maternal (39) and fetal (183) IGFBP1 concentrations have been 
shown to be negatively correlated with birth weight. We found that, compared to controls, 
placental IGFBP1 mRNA expression was significantly higher in women with SGA and lower in 
those with LGA fetuses (Figure 3.2, A). Western blot analysis showed a tendency for higher 
protein concentration in SGA neonates but this was not significant (Figure 3.2, B). However the 
protein concentration was significantly lower in the LGA neonates (Figure 3.2, C). 
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Figure 3.2 Placental IGFBP1 gene expression. (A) IGFBP1 mRNA expression in normal size (n = 37), SGA 
(n = 16) and LGA (n = 20) neonates. (B) Representative western blot and densitometry analysis for IGFBP1 
(28kDA) in SGA group (n = 16). (C) Representative western blot and densitometry analysis for IGFBP1 in 
LGA group (n = 20), *p < 0.05; **p < 0.005 vs. normal controls, mean ±SEM, Mann Whitney. Control with  
β-actin (42kDa) to correct protein loading.   
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3.3.2. Placental IGFBP2 gene expression 
  
It is known that IGFBP2 co-localises with IGF1 and IGF2 in the placenta thereby suggesting an 
important role in modulating IGF bioavailability (184). A previous report has shown an increased 
expression of IGFBP2 in growth restricted neonates (43). We found increased placental IGFBP2 
mRNA expression in SGA neonates and decreased expression in LGA neonates, compared to 
controls (Figure 3.3, A). This was supported by western blot analysis that showed a significantly 
raised IGFBP2 protein concentration in placentae from SGA neonates and decreased expression 
in LGA neonates (Figure 3.3, B and C). 
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Figure 3.3 Placental IGFBP2 gene expression.  (A) IGFBP2 mRNA expression in normal size (n = 37), SGA 
(n = 16) and LGA (n = 20) neonates. (B) Representative western blot and densitometry analysis for IGFBP2 
(36kDA) in SGA group (n = 16). (C) Representative western blot and densitometry analysis for IGFBP2 
(36kDA) in LGA group (n = 20), *p < 0.05; **p < 0.005 vs. normal controls, mean ±SEM, Mann Whitney. 
Control with β-actin (42kDA) to correct protein loading.   
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3.3.3. Placental IGFBP3 gene expression 
We report significantly higher IGFBP3 expression in SGA fetuses and lower in LGA  
fetuses, compared to controls (Figure 3.4, A). The placental protein content of IGFBP3 was 
higher in SGA and lower in LGA neonates thus supporting the mRNA expression findings 
(Figure 3.4, B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Placental IGFBP3 gene expression.  (A) IGFBP3 mRNA expression in normal size (n = 37), 
SGA (n = 16) and LGA (n = 20) neonates. (B) Representative western blot for IGFBP (32kDa) in SGA 
neonates (n = 16). (C) Representative western blot for IGFBP3 (32kDa) in LGA group (n = 20), *p < 0.05; 
**p < 0.05 vs. normal controls, mean ±SEM, Mann Whitney. Control with β-actin (42kDa) to correct 
protein loading.   
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3.3.4. Placental IGFBP4 gene expression 
An inverse correlation between maternal IGFBP4 levels and birth weight has been reported 
(47).  There is paucity of data on placental IGFBP4 gene expression in small and large 
neonates. It has been suggested that IGFBP4 may serve as a reservoir of IGF2 within the 
placental bed modulating the bioavailability of IGF2 (47). We found increased mRNA 
expression in SGA neonates and decreased expression in LGA neonates, compared to 
controls (Figure 3.5, A). Western blot analysis confirmed higher IGFBP4 protein expression 
in SGA neonates and decreased protein expression in LGA neonates (Figure 3.5, B & C). 
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Figure 3.5 Placental IGFBP4 gene expression. (A) IGFBP4 mRNA expression in normal size (n = 37), SGA 
(n = 16) and LGA (n = 20) neonates. (B) Representative western blot and densitometry analysis for IGFBP4 
(26kDa) in SGA neonates (n = 16). (C) Representative western blot and densitometry analysis for IGFBP4 
(26kDa) in LGA group (n = 20), *p < 0.05; **p < 0.005; ***p < 0.0005 vs. normal controls, mean ±SEM,  
Mann Whitney. Control with β-actin (42kDa) to correct protein loading.   
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3.3.5. Placental IGFBP5, IGFBP6 and IGFBP7 gene expression 
 
It has been shown that IGFBP5 and IGFBP6 are primarily present in the decidua (26) and 
were undetectable in our samples. IGFBP7 has been studied in HTR8 trophoblast cell line 
(48) but there are no reports describing its expression in term placenta. It has lower affinity 
for IGFs in comparison to the other IGFBPs (185).   
We have been able to demonstrate IGFBP7 expression in our samples and have shown it to be 
upregulated in the SGA group, compared to controls. However, there was no significant 
difference in its expression in the LGA neonates (Figure 3.6, A). Western blot analysis 
showed higher IGFBP7 protein levels in the placentae of the SGA neonates. (Figure 3.6, B). 
The protein expression of IGFBP7 was not analysed in the LGA group because there were no 
significant differences in the IGFBP7 mRNA expression. 
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Figure 3.6 Placental IGFBP7 gene expression. (A) IGFBP7 mRNA expression in normal size (n = 37), SGA 
(n = 16) and LGA (n = 20) neonates. (B) Representative western blot and densitometry analysis for IGFBP7 
(29kDa) in SGA neonates (n = 16), **p < 0.005 vs. normal controls, mean ±SEM, Mann Whitney. Control 
with β-actin (42kDa) to correct protein loading.   
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3.3.6. Correlation between placental mRNA expression and birthweight centiles 
 
Having shown the decreased placental expression of IGF1 in SGAs, increased expression of 
IGFBP1, IGFBP2, IGFBP3, IGFBP4 and IGFBP7 in SGAs and decreased expression of 
IGFBP1, IGFBP2, IGFBP3 and IGFBP4 in LGAs, compared to controls, we wanted to 
investigate the correlation between IGF1 and IGFBP mRNA expression and  birthweight 
percentiles. We found that IGF1 mRNA expression showed a significant positive correlation 
with birthweight percentiles, while IGF2 mRNA showed no significant correlation (Figure 3.7, 
A and B). 
 
 
 
         
 Figure 3.7 Correlation between IGF1 and IGF2 mRNA expression and birthweight percentiles.  
(A) IGF1 mRNA expression vs. birthweight percentiles, Rs = 0.22, p = 0.04.  (B) IGF2 mRNA expression vs. 
birthweight percentiles, Rs = 0.1, p = 0.4; p<0.05 = significant, Rs = Spearman’s coefficient. 
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The mRNA expression of all the binding proteins showed a negative correlation with the 
birthweight percentiles (Figure 3.8, A to E). 
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Figure 3.8 Correlation between IGFBP mRNA expression and birthweight percentiles.  
(A) IGFBP1 mRNA expression vs. birthweight percentiles, Rs = -0.8, p = 0.0001; (B) IGFBP2 mRNA expression 
vs. birthweight percentiles, Rs = -0.5, p = 0.0001 (C) IGFBP3 mRNA vs. birthweight percentiles,  
Rs = -0.6, p< 0.0001 (D) IGFBP4 mRNA expression vs. birthweight percentiles, Rs = -0.5, p = 0.0001 (E) IGFBP7 
mRNA expression vs. birthweight percentiles, Rs = -0.5, p = 0.0001 p<0.05 = significant, Rs = Spearman’s 
coefficient. 
 
3.4. Placental promoter methylation  
3.4.1. Placental methylation of IGF1 promoter 
The gene promoter is a sequence in the DNA which helps initiate the transcription of a gene. 
Promoters are usually located near the transcription start site (TSS) of the gene on the same 
strand and upstream on the DNA.  Promoter methylation has been shown to silence gene 
expression (82). To understand whether changes in gene expression were related to promoter 
DNA methylation we decided to analyse the methylation levels in the IGF1 promoter. A CpG is 
a region in the DNA where a cytosine (C) nucleotide occurs next to a guanine (G) nucleotide 
linked by a phosphate (p) bond. Three CpGs were selected 500bp upstream of the TSS (Figure 
3.9. A). All the three CpGs in the SGA group were found to be hypermethylated as compared to 
controls (Figure 3.9, B). We did not analyse DNA methylation in the LGA group because there 
were no mRNA expression changes in that cohort. 
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Figure 3.9 Placental methylation of IGF1 promoter. (A) CpGs identified 500bp upstream of transcription 
start site (TSS). CpG1 location - Chr12: 102874379; CpG2 location - Chr12: 102874496; CpG3 location - 
Chr12: 102874590. (B) CpGs 1, 2 and 3 were hypermethylated in placentae of SGA neonates (n = 9 in each 
group), *p<0.05 vs. normal controls, mean ±SEM, Mann Whitney). 
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3.4.2. Placental methylation of IGFBP1 promoter  
Three CpG sites were selected 500bp upstream to the TSS (Figure 3.10 A). The CpGs were 
found to be hypomethylated in the SGA neonates as compared to controls. However, there were 
no methylation differences in the LGA neonates, compared to controls (Figure 3.10, B). 
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Figure 3.10 Placental methylation of IGFBP1 promoter. (A) CpGs identified 500bp upstream of 
transcription start site (TSS). CpG4 location - Chr7: 45928068; CpG5 location - Chr7: 45928045; CpG6 
location - Chr7: 45928043. (B) CpGs 4, 5 and 6 were hypomethylated in placentae of SGA neonates (n = 9 in 
each group), *p<0.05 vs.  normal controls, mean ±SEM, Mann Whitney. 
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3.4.3. Placental methylation of IGFBP2 promoter  
We similarly identified three CpG sites 500bp upstream of the TSS. The IGFBP2 promoter 
methylation levels followed a similar trend to IGFBP1 promoter methylation (Figure 3.11, A). 
All the CpG sites showed significant hypomethylation in the SGA neonates as compared to 
controls. There were no methylation differences in the LGA subgroup, compared to controls 
(Figure 3.11, B). 
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Figure 3.11 Placental methylation of IGFBP2 promoter. (A) CpGs identified 500bp upstream of 
transcription start site (TSS). CpG14 location - Chr2:217497892; CpG15 location - Chr2: 217497890; CpG16 
location - Chr2:217497873. (B) CpGs 32, 33 and 34 were hypomethylated in placentae of SGA neonates (n = 9 
in each group), *p<0.05 vs. normal controls, mean ±SEM, Mann Whitney.  
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3.4.4. Placental methylation of IGFBP3 promoter 
 
We targeted five CpG sites upstream of the TSS on the IGFBP3 promoter (Figure 3.12, A). CpG 
sites 8, 9 and 12 showed significant hypomethylation in SGA neonates as compared to normal 
controls. CpG sites 10 and 11 showed no differences in the methylation in the SGA cohort. No 
methylation differences were observed in any of the CpG sites in the LGA neonates, compared 
to controls (Figure 3.12, B). 
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Figure 3.12 Placental methylation of IGFBP3 promoter.  (A) CpGs identified 500bp upstream of 
transcription start site (TSS). CpG8 location - Chr7:45960789; CpG9 location - Chr7:45960783; CpG10 
location - Chr7:45960768; CpG11 location - Chr7:45960765; CpG12 location - Chr7:45960750. (B) CpGs 8, 9 
and 12 were hypomethylated in placentae of SGA neonates (n = 9 in each group), *p<0.05 compared to normal 
controls, mean ±SEM, Mann Whitney.  
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3.4.5. Placental methylation of IGFBP4 promoter  
 
We selected a cluster of 7 CpGs 500bp upstream of TSS (Figure 3.13, A). CpGs 9, 10, 12, 13 
and 14 showed significant hypomethylation in SGA neonates, compared to controls, but not 
CpGs 11 and 15 of the IGFBP4 promoter. There were no methylation differences in the LGA 
neonates as compared to controls (Figure 3.13, B). 
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Figure 3.13 Placental methylation of IGFBP4 promoter. (A) CpGs identified 500bp upstream of 
transcription start site (TSS). CpG9 – 364bp Chr17: 38599564; CpG10 location - Chr17: 38599561; CpG11 
location - Chr17: 38599558; CpG12 location - Chr17: 38599555; CpG13 location - Chr17: 38599552; CpG14 
location - Chr17: 38599549; CpG15 location - Chr17: 38599546. (B) CpGs 9, 10, 12, 13 and 14 were 
hypomethylated in placentae of SGA neonates, *p<0.05 vs. n normal controls, mean ±SEM, Mann Whitney. 
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3.4.6.  Placental methylation of IGFBP7 promoter  
 
Five CpGs were analysed 500bp upstream of the TSS (Figure 3.14, A). Compared to controls, 
CpGs 38 and 39 were significantly hypomethylated in the SGA cohort but not 40, 41 and 42. 
There were no methylation differences in the LGA group compared to controls (Figure 3.14, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
      
0
10
20
30
CpG38 CpG39 CpG40 CpG41 CpG42
%
 I
G
F
B
P
7
 M
et
h
y
la
ti
o
n
 
Normal SGA Macro
Figure 3.14 Placental methylation of IGFBP7 promoter (A) CpGs identified 500bp upstream of 
transcription start site (TSS). CpG38 location - Chr4: 57975672; CpG39 location - Chr4: 57975657; CpG40 
location – Chr4: 57975652; CpG41 location - Chr4: 57975645; CpG42 location - Chr4: 57975641; (B) CpGs 
38 and 39 were hypomethylated in placentae of SGA neonates, *p<0.05 vs. normal controls, mean ±SEM, 
Mann Whitney. 
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    3.4.7. Correlation between promoter DNA methylation and mRNA expression 
 
Promoter methylation is known to silence gene expression (84). We therefore wanted to test 
the correlation between mRNA expression and the promoter methylation between the 
respective genes. The mRNA expression of the target genes was noted to mostly have a 
significant negative correlation to their respective promoter methylation levels (Table 3.1). 
 
CpGs Rs P 
IGF1 CpG1 -0.6275 0.0070* 
IGF1 CpG2 -0.7377 0.0007* 
IGF1 CpG3 -0.4044 0.1074 
IGFBP1 CpG4 -0.4728 0.0147* 
IGFBP1 CpG5 -0.6349 0.0005* 
IGFBP1 CpG6 -0.7005 < 0.0001* 
IGFBP2 CpG14 -0.7785 < 0.0001* 
IGFBP2 CpG15 -0.5856 0.0017* 
IGFBP2 CpG16 -0.6205 0.0007* 
IGFBP3 CpG8 -0.8086 < 0.0001* 
IGFBP3 CpG9 -0.6627 0.0002* 
IGFBP3 CpG10 -0.5104 0.0077* 
IGFBP3 CpG11 -0.4161 0.0432* 
IGFBP3 CpG12 -0.6306 0.0010* 
IGFBP4 CpG9 -0.5971 0.0021* 
IGFBP4 CpG10 -0.3923 0.0579 
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IGFBP4 CpG11 0.04471 0.8357 
IGFBP4 CpG12 -0.6726 0.0003* 
IGFBP4 CpG13 -0.6260 0.0011* 
IGFBP4 CpG14 -0.5158 0.0099* 
IGFBP4 CpG15 -0.1613 0.4515* 
IGFBP7 CpG38 -0.6501 0.0006* 
IGFBP7 CpG39 -0.6882 0.0002* 
IGFBP7 CpG40 0.1900 0.3739 
IGFBP7 CpG41 -0.2764 0.1910 
IGFBP7 CpG42 -0.05846 0.7861 
 
 
Table 3.1 Correlation between mRNA expression and promoter methylation 
Rs = Spearman’s coefficient, p<0.05 = significant. 
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3.4.8. Correlation between promoter DNA methylation and birthweight percentiles 
 
Having established a negative correlation between promoter methylation and gene expression, 
we further wanted to test the correlation between promoter methylation and birthweight 
percentiles. We found that IGF1 promoter methylation had a significant negative correlation to 
birthweight percentiles while the binding protein methylation had a significant positive 
correlation to birthweight percentiles (Table 3.2). 
 
CpGs Rs P 
IGF1 CpG1 -0.62 <0.0001* 
IGF1 CpG2 -0.73 <0.0001* 
IGF1 CpG3 -0.80 <0.0001* 
IGFBP1 CpG4 0.41 <0.05* 
IGFBP1 CpG5 0.51 <0.01* 
IGFBP1 CpG6 0.46 <0.01* 
IGFBP2 CpG14 0.52 <0.01* 
IGFBP2 CpG15 0.63 <0.01* 
IGFBP2 CpG16 0.71 <0.01* 
IGFBP3 CpG8 0.55 <0.01* 
IGFBP3 CpG9 0.62 <0.05* 
IGFBP3 CpG10 0.71 <0.01* 
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IGFBP3 CpG11 0.74 <0.01* 
IGFBP3 CpG12 0.66 <0.05* 
IGFBP4 CpG9 0.50 <0.05* 
IGFBP4 CpG10 0.66 <0.01* 
IGFBP4 CpG11 0.73 <0.01* 
IGFBP4 CpG12 0.67 <0.01* 
IGFBP4 CpG13 0.58 <0.01* 
IGFBP4 CpG14 0.68 <0.01* 
IGFBP4 CpG15 0.71 <0.01* 
IGFBP7 CpG38 0.41 <0.05* 
IGFBP7 CpG39 0.45 <0.05* 
IGFBP7 CpG40 0.51 <0.05* 
IGFBP7 CpG41 0.61 <0.01* 
IGFBP7 CpG42 0.43 <0.01* 
 
 
Table 3.2 Correlation between placental promoter methylation and birthweight percentiles.  
Rs = Spearman’s coefficient, p<0.05 = significant. 
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3.5. Umbilical cord blood levels  
Our aim was to investigate whether there are differences in the umbilical levels of IGF1 and the 
binding proteins in fetal growth disorders. Umbilical venous samples were obtained and 
analysed using a multiplex ELISA quantibody platform. 
 
3.5.1. Umbilical level of IGF1in normal, SGA and LGA neonates 
 
The umbilical level of IGF1 did not show statistically significant differences between any of the 
groups examined.  However, the levels tended to be lower in the SGA and higher in LGA 
neonates compared to controls (Figure 3.15). 
 
 
 
 
 
 
 
 
Figure 3.15 IGF1 umbilical venous levels in normal, SGA and LGA neonates.  
SGA, p = 0.2; LGA, p = 0.1 vs. normal controls, mean ±SEM, Mann Whitney (n = 15 in each group). 
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3.5.2. Umbilical level of IGBP1 in normal, SGA and LGA neonates 
 
There was no significant difference in the umbilical cord level of IGFBP1 between the SGA 
neonates and controls. However, the IGFBP1 level in the umbilical cord blood was lower in the 
LGA neonates compared with that from control neonates (Figure 3.16). 
 
 
 
 
 
 
 
Figure 3.16 IGFBP1 umbilical venous levels in normal, SGA and LGA neonates.  
IGFBP1 level was not significantly different in the SGA group, but was significantly lower in the LGA group, (n = 
15 in each group), *p = 0.02 vs. normal controls, mean ±SEM, Mann Whitney. 
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3.5.3. IGFBP2 umbilical levels in normal, SGA and LGA neonates 
 
The umbilical IGFBP2 cord levels in the SGA neonates were significantly higher compared to 
controls. But there was no significant difference between the LGA neonates and controls (Figure 
3.17). 
 
 
 
 
 
 
 
 
Figure 3.17  IGFBP2 umbilical venous levels in normal, SGA and LGA neonates. 
IGFBP2 levels were significantly higher in the SGA group as compared to normal controls, *p = 0.01 vs. normal 
controls, mean ±SEM, Mann Whitney (n = 15 in each group). 
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3.5.4. IGFBP3 umbilical levels in normal, SGA and LGA neonates 
 
A similar trend in the umbilical cord IGFBP3 levels to the IGFBP2 levels was observed. The 
IGFBP3 levels were higher in SGA neonates but not different in the LGA neonates, compared to 
controls (Figure 3.18). 
 
 
 
 
 
 
 
Figure 3.18  IGFBP3 umbilical venous levels in normal, SGA and LGA neonates. *p=0.02 vs. normal controls, 
mean ±SEM, Mann Whitney (n = 15 in each group) 
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3.5.5. IGFBP4 umbilical levels in normal, SGA and LGA neonates 
 
The IGFBP4 cord levels in the LGA neonates were significantly lower compared to controls. No 
significant differences were found between SGA neonates and controls (Figure 3.19). 
 
 
 
 
 
 
 
Figure 3.19  IGFBP4 umbilical venous levels in normal, SGA and LGA neonates 
IGFBP4 levels were significantly lower in the LGA neonates as compared to normal controls, *p = 0.001 vs. 
normal controls, mean ±SEM, Mann Whitney (n = 15 in each group). 
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3.5.6. Correlation of umbilical levels and birthweight percentiles. 
Umbilical IGFs and IGFBPs have been correlated with fetal growth and have been shown to 
exert a net IGF activity due to their regulatory and counter-regulatory roles (186). We therefore 
focussed on investigating the correlation between umbilical cord levels of IGF1, IGFBP1, 
IGFBP2, IGFBP3 and IGFBP4 and birthweight percentiles. IGF1 umbilical levels were found to 
have significant positive correlation with birthweight percentiles, while IGFBP1, IGFBP2 and 
IGFBP4 umbilical levels were found to have significant negative correlation with birthweight 
percentiles (Figure 3.20, A to E). 
 
 
 
                  
0
2000
4000
6000
8000
10000
12000
0 20 40 60 80 100
IG
F
1
 u
m
b
il
ic
al
 l
ev
el
s 
p
g/
m
l 
birthweight percentiles 
0
2000
4000
6000
8000
10000
12000
14000
0 20 40 60 80 100
IG
F
B
P
1
 u
m
b
il
ic
al
 l
ev
el
s 
p
g
/m
l 
birthweight percentiles 
0
20000
40000
60000
80000
100000
0 20 40 60 80 100
IG
F
B
P
2
 u
m
b
il
ic
al
 l
ev
el
s 
p
g
/m
l 
birthweight percentiles 
A 
B C 
100 
 
            
                                                                                                                                                           
            Figure 3.20 Correlation between umbilical levels and birthweight percentiles.  
              Umbilical IGF1 levels had a positive correlation while IGFBP1, IGFBP2 and IGFBP4 had a negative      
correlation with birthweight percentiles. (A) IGF1, Rs = 0.42, p =0.01; (B) IGFBP1, Rs = -0.44, p = 0.003; (C) 
IGFBP2, Rs = -0.33, p = 0.03; (D) IGFBP3, Rs = -0.09, p = 0.56; (E) IGFBP4, Rs = -0.37, p = 0.01;  
Rs = Spearman’s coefficient, p<0.05 = significant. 
 
3.6. In silico transcription factor prediction 
 
The molecular consequence of CpG methylation is the interruption of transcription factor (TF) – 
DNA interactions either directly or indirectly by engaging methylated DNA binding proteins 
which compete for the TF binding sites (187). To understand whether the differential 
methylation changes observed in our cohort could be functionally relevant we investigated the 
potential transcription factor binding sites located in the region of the gene promoters. Several 
transcription factors were predicted in the promoter regions of IGF1 and its binding proteins 
(Table 3.1) using the predictor tool, PROMO (version 3.0.2) (http://alggen.lsi.upc.es/cgi-
in/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 (188) 
 
 
0
50000
100000
150000
200000
250000
300000
0 20 40 60 80 100
IG
F
B
P
3
 u
m
b
il
ic
al
 l
ev
el
s 
p
g/
m
l 
birthweight percentiles 
0
40000
80000
120000
160000
200000
0 20 40 60 80 100
IG
F
B
P
4
 u
m
b
il
ic
al
 l
ev
el
s 
p
g
/m
l 
birthweight percentiles 
D E 
101 
 
Gene CpG number CpG location Transcription factor 
prediction 
IGF1 1 Chr12: 102874390 MEF-2A, GR-β, XBP-1 
IGF1 2 Chr12: 102874496 FOXP3, GR-β 
IGF1 3 Chr12: 102874579  RXR-α, GATA-1 
IGFBP1 4 Chr7: 45928068 C/EBPα, CTF, NF-1, E2F-1 
IGFBP1 5 Chr7: 45928045 C/EBPα, CTF, NF-1, E2F-1 
IGFBP1 6 Chr7: 45928043 C/EBPβ 
IGFBP2 14 Chr2: 217497892 TFII-I 
IGFBP2 15 Chr2: 217497890 TFII-I 
IGFBP2 16 Chr2: 217497873 E2F-1,  
IGFBP3 8 Chr7: 45960789 GR-β, TFIID, HNF-3α 
IGFBP3 9 Chr7: 45960783 FOXP3 
IGFBP4 11 Chr17: 45960768 WT1 
IGFBP4 12 Chr17: 45960765 E2F-1 
IGFBP4 13 Chr17: 45960750 GR-β 
IGFBP4 15 Chr17: 38599564 E2F-1 
IGFBP7 38 Chr4: 38599561 C/EBPalpha, GR- β 
IGFBP7 39 Chr4: 38599558 C/EBPbeta 
IGFBP7 40 Chr4: 38599552 C/EBPβ, GR-α, RAR-β, TFIID,  
IGFBP7 42 Chr4: 38599549 RXR-α 
 
Table 3.3 Transcription factor prediction 
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3.7. Summary and Discussion 
Our study has demonstrated that in pregnancies affected by SGA the placental IGF and IGFBP 
axis is altered. We have found that in pregnancies with small fetuses placental IGF1 mRNA 
expression is decreased and the IGFBPs expression is increased and these changes are associated 
with alteration in the methylation level with IGF1 being hypermethylated and IGFBPs being 
hypomethylated. These findings indicate that epigenetic modification may be playing a key role 
in regulating fetal growth. On the contrary, in the pregnancies with large neonates, the 
differences in gene expression could not be explained by corresponding methylation changes in 
the respective gene promoters.  
 
Various reports have described IGF and IGFBP gene expression in fetuses affected by growth 
disorders, however these studies were limited by variables such as sample size, number of 
binding proteins investigated and type of tissue/serum used (32,189–191). We found IGF1 gene 
expression to be lower in SGA group which is in agreement with previous studies (32,38). It is 
well known that altered DNA methylation can be a part of disease pathogenesis (192). The IGF1 
gene promoter was found to be hypermethylated in the placenta of SGA neonates. Importantly, 
mRNA expression had a significant positive correlation with birthweight while the IGF1 
promoter methylation had a significant negative correlation. This inverse relationship between 
gene expression, promoter methylation and birth weight suggests epigenetic control of IGF1 in 
the pathogenesis of fetal growth restriction. IGF1 was not differentially expressed in LGA 
neonates which is in agreement with a recent report (193) and IGF2 expression was similar 
across all the subgroups in agreement with a previous study (194). 
 
We found elevated mRNA and protein levels of IGFBP1, IGFBP2, IGFBP3, IGFBP4 and 
IGFBP7 in placenta of SGA neonates and decreased expression of IGFBP1, IGFBP2, IGFBP3 
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and IGFBP4 in the LGA group. Corresponding to these changes in gene expression, the 
promoters of the respective genes were hypomethylated in the SGA but the methylation changes 
were not significant in the LGA group. There was a significant negative correlation for IGFBPs 
1, 2, 3, 4 and 7 mRNA expression with birth weight percentiles while promoter methylation of 
all the binding proteins showed a significant positive correlation with them. While some studies 
have shown an inverse correlation of IGFBP1 and IGFBP2 with birth weight (177,195) there is 
conflicting data regarding IGFBP3 gene expression and paucity of data describing IGFBP4, 
IGFBP5 and IGFBP6 expression in placentas of  small or large neonates (44,45,196).  IGFBP5 
and IGFBP6 could not be detected in our samples. This may be due to their expression being 
restricted to the decidua (26,42) rather than the fetal side from where our samples were 
collected. IGFBP7 gene expression has not been previously investigated in small or large 
neonates in human term placenta. An inverse correlation of promoter methylation and mRNA 
expression may suggest DNA methylation plays a crucial role in the gene expression of the 
binding proteins and therefore impacting in the pathogenesis of small fetal size. Since we did not 
find significant differences in the IGF1 mRNA expression in the LGA neonates we did not 
perform methylation analysis on this cohort. However there were no methylation differences in 
the promoters of the binding proteins in the LGA neonates. It is possible that DNA methylation 
plays an important role in the pathogenesis of small fetal size while other epigenetic mechanisms 
like microRNAs or histone modifications may be at play in the pathogenesis of macrosomia. We 
found a trend of IGF1 umbilical levels to be lower in the SGA and higher in the LGA neonates. 
The umbilical levels of IGFBP1 and IGBP4 were significantly lower in LGA while IGFBP2 and 
IGFBP3 levels were significantly increased in the SGA neonates. This showed some similarity 
in the trend of the placental gene expression profile. When the umbilical levels were correlated 
with birthweight percentiles, IGF1 levels showed a positive correlation while IGFBP1, IGFBP2 
and IGFBP4 levels showed a negative correlation. Although regulation of umbilical levels is 
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under fetal control it could be hypothesised that some trend similarities could be a reflection of 
the changes exerted by the placental epigenetic and genetic milieu. One of the mechanisms by 
which DNA methylation is thought to silence gene expression is by impeding the binding of  
transcription factors (197). In silico analysis was undertaken to further understand which 
transcription factors, could potentially bind to the target CpG sites in the gene promoters. 
Binding sites were predicted for monocyte enhancing factor 2A (MEF-2A), Retinoid x receptor 
α (RXR- α) and erythroid transcription factor 1 (GATA-1) within the range of CpG 1 of IGF1 
promoter. Various other transcription factors predicted in the promoters of the binding proteins 
such as FOX-P3, E2F1, RXR-α, GR-β, WT1 and TFIID are known to be involved in regulation 
of cellular growth, apoptosis, stress and inflammatory responses (198–200). This provides an 
exciting new challenge to identify these TFs in the placenta and also to investigate their role in 
gene expression. 
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4.  Epigenetic, transcriptional and translational variation in placental IGFs 
and its binding proteins in gestational diabetes mellitus. 
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4.1. Introduction 
Gestational diabetes mellitus (GDM) has a prevalence of about 3.5% in the UK (201). It is 
known that intrauterine hyperglycaemia predisposes the offspring to diabetes, hypertension and 
metabolic disease (154–156). The exact mechanisms by which a diabetic environment confers 
risk to the fetus is still unclear however in vitro experiments have shown hyperglycaemia and 
hyperinsulinaemia to alter epigenetic mechanisms (157,158). One of the most convincing 
evidence that the diabetic intrauterine environment increases the risk of metabolic disease in 
offspring is from a discordant sibling study (202) where the authors showed that the risk of 
diabetes was significantly higher in the offspring born after the mother had developed diabetes 
than those born before the mother’s diagnosis. There is evidence that the diabetic intrauterine 
environment can epigenetically alter pathways involved in complex diseases (161) and can also 
potentially transmit the adverse effects to the next generation (203). Apart from bearing a close 
structural homology to insulin (58), IGFs are also regulated by glucose and insulin (26). There is 
one report (204) investigating placental DNA methylation of the IGF system related genes in 
GDM where only IGFBP3 was investigated. The aim of the current study was to investigate 
differences in placental gene expression and DNA methylation of the IGF system related genes 
in women with GDM compared to those with uncomplicated pregnancies and whether these 
differences correlated with maternal glucose levels and neonatal birth weight. It is known that 
normal sizes neonates born to women with raised BMI are at risk of developing diabetes in adult 
life (205). We therefore wanted to understand if the IGF axis was differentially regulated in 
women with increased BMI as compared to women with normal BMI. All placental samples 
were collected from the fetal side of the placenta around the umbilical cord insertion from 
women delivering at term, the cord blood samples were collected from the umbilical vein and 
the cohort was matched for variables such as maternal age, BMI, race, parity and smoking 
(Table 2.2), thus ensuring consistency unlike previous studies.  
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4.2. Altered gene expression of the IGF axis in GDM and raised maternal BMI 
 
We wanted to investigate if the IGF axis was differentially expressed in placentae of women 
with GDM and women with high BMI (>30) with normal sized neonates. Placental expression of 
IGF1, IGFBP1 and IGFBP2 was found to be significantly downregulated in women with GDM 
but not affected in increased BMI. The expression of IGF2 and the rest of the binding proteins 
were not different in GDM. None of the target genes showed differential regulation in women 
with raised BMI (Figure 4.1, A to G). 
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Figure 4.1 Placental IGF and IGFBP expression in women with GDM and raised BMI. 
(A) IGF1 expression, (B) IGF2 expression, (C) IGFBP1 expression, (D) IGFBP2 expression, (E) IGFBP3 
expression, (F) IGFBP4 expression, (G) IGFBP7 expression. Normal, n = 37, GDM, n = 60,  
raised BMI, n = 14; *p<0.05, ** p<0.005 vs.  normal controls, mean ±SEM, Mann Whitney.  
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4.3. Altered expression of the IGF axis in women with GDM according to treatment. 
 
Since we did not find differences in the mRNA expression in the raised BMI cohort, we 
focussed on the GDM cohort where we found significant differences. After establishing the 
placental downregulation of IGF1, IGFBP1 and IGFBP2 in women with GDM compared to 
controls, we categorised the GDM group according to treatment, i.e. those on diet, diet and 
metformin, and diet and insulin. There was significant downregulation of IGF1, IGFBP1 and 
IGFBP2 in women on diet with or without metformin but not in women treated with insulin 
(Figure 4.2, A to F).  
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Figure 4.2 Placental IGF1, IGFBP1 and IGFBP2 mRNA and representative protein expression in women 
with GDM on different treatments. 
(A) IGF1 mRNA expression; (B) Representative western blot of IGF1 (8kDa); (C) IGFBP1 mRNA expression;  
(D) Representative western blot of IGFBP1 (28kDa); (E) IGFBP2 mRNA expression; (F) Representative western 
blot of IGFBP2 (36kDa). Normal (n = 37), GDM on diet and metformin (n = 23 each) and on insulin (n = 14), 
*p<0.05, ** p<0.005, *** p<0.0005 vs. normal controls, mean ±SEM, Mann Whitney. Control with β-actin to 
correct for protein loading.   
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There were no differences in the IGF2, IGFBP3, IGFBP4 and IGFBP7 expression in women 
with GDM on different treatments (Figure 4.3 A to D).  
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Figure 4.3 Placental IGF2, IGFBP3, IGFBP4 and IGFBP7 expression in women with GDM on different 
treatments. 
(A) IGFBP2 expression, p = 0.23 (B) IGFBP3 expression, p =0.31(C) IGFBP4 expression, p = 0.1, (D) 
IGFBP7 expression, p = 0.26.  Normal (n = 37), GDM on diet and metformin (n = 23 each) and on insulin (n = 
14), p<0.05 = significant, mean ±SEM, Mann Whitney. 
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4.4. Correlation between mRNA expression and birthweight percentiles  
We have shown that IGF1 mRNA expression has a strong positive correlation with birthweight 
and the binding protein expression had a strong negative correlation with birthweight in fetuses 
affected by growth disorders (Figure 3.7). We wanted to understand if there was a similar 
association in the diabetic placenta. There was no correlation between mRNA expression of 
placental IGFs and any of their binding proteins with birthweight percentiles in women with 
GDM (Figure 4.4, A to G). 
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Figure 4.4 Correlation between mRNA expression and birthweight percentiles. (A) IGF1, Rs = 0.12, p = 0.22, 
(B) IGF2, Rs = 0.005, p = 0.96, (C) IGFBP1, Rs = 0.11, p = 0.28 (D) IGFBP2, Rs = 0.09, p = 0.34, (E) IGFBP3, Rs = 
-0.06, p = 0.54 (F) IGFBP4, Rs = -0.008, p = 0.93 (G) IGFBP7. Rs = -0.13, p = 0.16, Rs = Spearman’s coefficient, 
p<0.05 = significant. 
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4.5. Altered placental DNA methylation in women with GDM 
 
We wanted to test whether promoter methylation plays a role in regulating gene expression in 
the gestational diabetic placenta, CpG methylation was analysed in the promoters upstream of 
the transcription start site (TSS) of IGF1, IGFBP1 and IGFBP2 since these three genes were 
found to be differentially expressed. The CpGs were selected in the region of 500bp upstream of 
the TSS of the three genes (Figures 3.9 to 3.11). For the IGFBP1 gene promoter we analysed the 
three CpGs in the fetal growth cohort (Figure 3.10, A) and two additional CpGs (Figure 4.5). 
 
 
 
 
 
 
 
Figure 4.5 Target CpGs 500bp upstream of the transcription start site (TSS) of IGFBP1 gene 
 CpGs identified 500bp upstream of transcription start site (TSS). CpG4 location - Chr7: 45928068; CpG5 
location - Chr7: 45928045; CpG6 location - Chr7: 45928043, CpG7location – Chr7: 45928010, CpG8 location 
- Chr7: 45928007 
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Majority of the CpGs in the IGF1, IGFBP1 and IGFBP2 promoters showed hypermethylation in 
women only on diet treatment but not on metformin or insulin (Figure 4.6, A to C). 
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Figure 4.6 Placental IGF1, IGFBP1 and IGFBP2 promoter methylation in controls and women with GDM on 
different treatments. 
(A) IGF1 promoter methylation – CpG sites 1, 2 and 3; (B) IGFBP1 promoter methylation - CpG sites 4, 5, 6, 7, and 
8 (C) IGFBP2 promoter methylation – CpG sites 32, 33, 34; *p<0.05, **p<0.005, ***p<0.0005 when compared to 
normal controls (n = 9 in each group), mean ±SEM, Mann Whitney.  
 
 
4.5.1. Correlation between promoter methylation and mRNA expression  
 
We have shown a significant inverse correlation between placental IGF1, IGFBP1 and IGFBP2 
promoter methylation and their respective mRNA expression in the non-diabetic placenta in 
women with fetal growth disorders (Table 3.1). However when the methylations of these genes 
were compared to their mRNA expression in the diabetic placenta, not all CpGs showed a 
significant negative association. For example the correlation of methylations at CpG1 of IGF1 
promoter, CpG6 of the IGFBP1 promoter and CpG16 of the IGFBP2 promoter (Table 3.1) with 
their respective mRNA expression were no longer significant, unlike in the non-diabetic placenta 
(Table 4.1). 
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CpGs Rs P 
IGF1 CpG1 0.2 0.12 
IGF1 CpG2 -0.04 0.02* 
IGF1 CpG3 -0.2 0.19 
IGFBP1 CpG4 -0.3 0.03* 
IGFBP1 CpG5 -0.3 <0.01* 
IGFBP1 CpG6 -0.2 0.1 
IGFBP1 CpG7 -0.3 0.04* 
IGFBP1 CpG8 -0.03 0.8 
IGFBP2 CpG14 -0.3 0.03* 
IGFBP2 CpG15 -0.3 0.03* 
IGFBP2 CpG16 0.09 0.56 
 
 
Table 4.1 Correlation between promoter methylation and mRNA expression 
Rs = Spearman’s coefficient, p<0.05 = significant. 
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4.5.2 Correlation between promoter methylation and fasting glucose tolerance levels  
It is known that glucose can cross the placenta but insulin cannot (206). Furthermore glycaemic 
changes are associated with long term epigenetic changes (207). The placental methylation 
levels were correlated with fasting glucose concentrations at the 28 weeks oral glucose tolerance 
test (OGTT). The methylation levels of most the CpGs in the promoters of IGF1, IGFBP1 and 
IGFBP2 had a negative correlation to the fasting glucose levels with IGF1 CpGs 2 and 3 and 
IGFBP2 CpG 14 showing significance (Table 4.2). 
CpGs Rs P 
IGF1 CpG1 -0.19 0.35 
IGF1 CpG2 -0.54 0.004* 
IGF1 CpG3 -0.43 0.02* 
IGFBP1 CpG4 -0.23 0.26 
IGFBP1 CpG5 -0.18 0.3 
IGFBP1 CpG6 -0.13 0.53 
IGFBP1 CpG7 -0.19 0.35 
IGFBP1 CpG8 0.1 0.62 
IGFBP2 CpG14 -0.28 0.17 
IGFBP2 CpG15 -0.4 0.04* 
IGFBP2 CpG16 0.19 0.63 
 Table 4.2 Spearman’s correlation between placental methylation and maternal fasting glucose levels 
Rs = Spearman’s coefficient, *p<0.05 = significant. 
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4.5.3. Correlation between promoter methylation and birthweight percentiles in GDM 
 
We have shown that methylation of most of the CpGs of the IGF1 promoter showed a negative 
correlation and most of the CpGs of the binding proteins promoter showed a positive correlation 
with birthweight percentiles in placentae of fetuses affected by growth disorders (Table 3.1, 
Chapter 3). We wanted to test if a similar association existed between the IGF1, IGFBP1 and 
IGFP2 methylation in the gestational diabetic placentae. All the CpGs at the IGF1 promoters 
showed a negative correlation with birthweight percentiles; however this was not significant. All 
the CpGs at the IGFBP1 promoters showed a positive correlation with birthweight percentiles 
but only CpGs 4, 6 and 8 achieving significance. None of the CpGs at the IGFBP2 promoters 
showed any association with the birthweight percentiles (Table 4.3). 
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CpGs Rs P 
IGF1 CpG1 -0.11 0.5 
IGF1 CpG2 -0.15 0.36 
IGF1 CpG3 -0.1 0.53 
IGFBP1 CpG4 0.35 0.03* 
IGFBP1 CpG5 0.09 0.5 
IGFBP1 CpG6 0.3 0.01* 
IGFBP1 CpG7 0.19 0.24 
IGFBP1 CpG8 0.35 0.03* 
IGFBP2 CpG14 0.1 0.55 
IGFBP2 CpG15 0.03 0.84 
IGFBP2 CpG16 -0.01 0.93 
 
Table 4.3 Correlation between promoter methylation and birthweight percentiles 
Rs = Spearman’s coefficient, *p<0.05 = significant. 
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4.6. Umbilical cord levels in women with GDM 
 
Having established gene expression and epigenetic changes in the expression of IGF1, IGFBP1 
and IGFBP2 in women with GDM, we focussed on their circulatory levels in the umbilical cord 
to understand if there was a similar trend. Previous reports studying the IGF1 and IGFBP1 levels 
in cord blood have shown inconsistent results (208–211). Furthermore, these studies were 
mainly on investigating umbilical cord levels only and did not investigate placental expression in 
the same cohort. We analysed 14 umbilical venous samples each of normal controls, GDM 
treated by diet only, GDM on diet and metformin and GDM on diet and insulin. All samples 
were analysed using the multiplex ELISA quantibody platform. These samples included the 
cohort of women whose placental samples were tested for methylation analysis. We found IGF1 
and IGFBP1 but not IGFBP2 umbilical levels to be significantly higher in the entire GDM 
cohort irrespective of treatment (Figure 4.7, A to C).  
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Figure 4.7 Umbilical cord levels in normal controls and the entire GDM cohort.  
(A) IGF1 umbilical levels, (B) IGFBP1 umbilical levels, (C) IGFBP2 umbilical levels.  
*p<0.05, **p<0.005 vs. normal controls, mean ±SEM, Mann Whitney. (n = 14 in each group). 
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When the GDM cohort was divided according to treatment, the IGF1 umbilical levels were 
found to be significantly higher in women with GDM treated with diet or metformin but not in 
those treated with insulin. The IGFBP1 umbilical levels were found to be higher in all the GDM 
subgroups, compared to normal controls, while there was no significant difference in the levels 
of IGFBP2 (Figure 4.8, A to C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Umbilical levels of IGF1, IGFBP1 and  IGFBP2 in normal controls and in women with GDM on 
different treatments 
(A) IGF1 levels, (B) IGFBP1 levels, (C) IGFBP2 levels, (D) IGBP3 levels and (E) IGFBP4 levels.  
*p<0.05, **p<0.005, ***p<0.0005, vs. normal controls, mean ±SEM, Mann Whitney (n = 14 in each group). 
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4.7. Correlation of umbilical levels with birthweight percentiles in GDM 
 
Having established an inverse correlation between umbilical serum levels of IGF1 and the 
binding proteins with birthweight percentiles in fetuses with growth disorders we tested if a 
similar correlation in women with GDM. The IGF1, IGFBP1 and IGFBP2 levels showed no 
significant association with birthweight percentiles (Figure 4.9, A to C). 
      
                                                                 
         
 
 
Figure 4.9 Correlation between umbilical cord levels of IGF1, IGFBP1 and IGFBP2 and birthweight 
percentiles. (A) IGF1, Rs = 0.03, p = 0.98; (B) IGFBP1, Rs = 0.14, p = 0.3; (C) IGFBP2, RS = 0.02, p = 0.83  
(n = 14 in each group). 
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4.8. Summary and Discussion  
 
Although hyperinsulinaemia is the most important cause for the adverse effects of GDM, the 
role of the IGF axis in mediating actions of insulin on the intrauterine environment is still 
unclear. Our work has demonstrated that placental IGF1, IGFBP1 and IGFBP2 genes are 
differentially regulated in women with GDM and we have shown that there are methylation 
differences in these genes in women with GDM treated with diet alone but not on those 
receiving pharmacological treatment. Finally, we have further established that the 
methylation levels of IGF1, IGFBP1 and IGFBP2 correlate negatively with maternal glucose 
fasting levels at the time of the full OGTT at 28 weeks of gestation. As we found no 
differences in the mRNA expression of IGFBP3, IGFBP4 and IGFBP7 in the GDM cohort of 
women these genes were not studied further. We were unable to detect IGFBP5 and IGFBP6 
in our samples. This may be due to their expression being restricted to the decidua (26,42) 
rather than the fetal side of the placenta from where our samples were collected.  
 
We found IGF1, IGFBP1 and IGFBP2 placental expression to be significantly downregulated 
in women with GDM especially in women on diet and metformin treatment but not in those 
on insulin (Figure 4.2). This might suggest an endocrine role of insulin to regulate placental 
gene expression in a diabetic placenta. IGF1, IGFBP1 and IGFBP2 are known to play a 
crucial role in glucose homeostasis and metabolism. Our findings of reduced expression are 
in agreement with animal studies which have shown that inactivating IGF1 gene is associated 
with insulin insensitivity and hyperinsulinaemia (58). IGFBP1 and IGFBP2 genes are also 
known to be suppressed by insulin and carbohydrate intake (212). Qiu et al (213) has reported 
an inverse correlation of maternal IGF1 and IGFBP1 with subsequent risk of developing 
GDM. Animal studies have shown that administration of IGFBP2 to obese mice improves 
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insulin sensitivity (214). None of the genes had significantly different placental mRNA 
expression in women with raised BMI; hence further tests were not undertaken on this cohort. 
Although there is a report describing reduced IGFBP4 umbilical cord levels in women with 
raised BMI (78), there is dearth of information about placental expression of the IGF system 
in women with raised BMI. All the obese women in our cohort were carefully selected not to 
have any detectable comorbidities like diabetes. We found that expression levels of IGF1, 
IGFBP1 and IGFBP2 genes between normal and obese women was similar and that may be a 
reflection of the attenuation of the growth potentiating effects of maternal obesity on fetal 
growth, as an evolutionary mechanism protecting against excessive fetal growth which may 
not be supported in the postnatal environment. 
 
When DNA methylation of the promoter sequences of IGF1, IGFBP1 and IGFBP2 were 
analysed in our GDM cohort of women according to different treatments (diet, metformin and 
insulin) we found that the promoters of all three genes were hypermethylated in the GDM 
cohort irrespective of treatment but interestingly this was significant only on those women on 
diet treatment and not in the metformin or insulin group. The methylation changes could be 
hypothesised to be related to altered glucose levels especially since it has been shown that 
even transiently high glucose can cause persistent epigenetic changes and alter gene 
expression (215). There was a trend of negative correlation between the promoter methylation 
and gene expression of IGF1, IGFBP1 and IGFBP2 in the diabetic placenta. However it is 
interesting to note that the significant negative correlation, which was seen between 
methylation of specific CpGs and gene expression in the non-diabetic placentae of women 
with growth disorder neonates, was lost when the same CpGs were analysed in the diabetic 
placenta. It is also interesting to find that the significant correlation between IGF1, IGFBP1 
and IGFBP2 methylation and birthweight percentiles as seen in the growth disorder cohort 
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was not observed in the diabetic cohort. The methylation of only three CpGs 4, 6 and 8 of 
IGFBP1 showed a significant positive correlation to birthweight percentiles. This reflects that 
the methylation of these CpGs could be influenced by environmental factors such as altered 
glucose levels and therefore affecting gene expression and birthweight.  
 
We found methylation levels of most of the CpGs tested to have a trend of inverse correlation 
with maternal fasting glucose levels and a similar trend with the 2 hour post glucose load of 
the OGTT.  This is biologically plausible since it is known that insulin does not pass through 
the placenta but glucose does. This could suggest glucose affecting the epigenetic profile. 
This hypothesis gets stronger on the premise that even transient hyperglycemia, can induce 
persistent epigenetic changes and can result in changes that are long lasting even after 
glycemic control is restored (207,215).  
 
The umbilical levels of IGF1 and IGFBP1 were found to be higher in women with GDM as 
compared to normal controls; which is in agreement with previous studies (210,216). The 
IGFBP2 umbilical levels also appeared to increase in comparison to normal controls. The 
decreased placental expression of IGF1, IGFBP1 and IGFBP2 in women with GDM and the 
contradictory increased umbilical cord levels of these proteins could be due to a counter-
regulatory response from the fetus in response to the altered maternal diabetic milieu.  
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5. Placental GRB10 expression in women with fetal growth disorders  
and gestational diabetes mellitus 
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5.1. Introduction 
 
GRB10 is an imprinted gene under epigenetic control that belongs to a small family of adaptor 
proteins that includes GRB7 and GRB14 (217). GRB10 is a cytoplasmic protein mediating 
coupling of various cell surface receptor tyrosine kinases (218) and is known to interact with 
insulin receptor and insulin-like growth factor receptor InsR and IGF1R (217). GRB10 is known 
to play a crucial role in fetal growth (219,220) and although the role of GRB10 in tyrosine 
kinase signalling is still controversial, mice studies have shown it to have a growth inhibiting 
role (167,221). In vitro studies with chinese hamster ovary (CHO) cells have shown GRB10 to 
have an inhibitory effect on the downstream events of the tyrosine kinase pathway (163). Animal 
studies have shown that increased expression can cause fetal growth retardation (222) while 
decreased expression can lead to overgrowth (167). GRB10 is also known to be involved in 
glucose homeostasis and is a known negative regulator of insulin sensitivity (223,224). GRB10 
knockout mice show improved insulin sensitivity in skeletal muscle and adipose tissue (224). 
There is scarcity of data about its expression in the maternal circulation, placenta or the 
umbilical cord. There is one study where the methylation of the GRB10 gene was identified as 
one of the six genes associated with 70-87% of the variance in birth weight. Furthermore it was 
correlated with the transcriptional control of gene networks that determine growth control (225). 
As GRB10 plays an important role in fetal growth and interacts with the IGF axis our aim was to 
further analyse GRB10 expression in our cohort of women. 
. 
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5.2. Placental GRB10 expression in fetal growth disorders 
 
The regulation of GRB10 expression is by genomic imprinting (218). The maternally inherited 
copy of GRB10 is predominantly expressed during embryogenesis. Being maternally expressed 
it is expected that GRB10 would limit growth as shown by several mice studies (167,221,226). 
Deletion of the maternally inherited copy of GRB10 has been shown to result in placental and 
fetal overgrowth in mice (167). There is dearth of human studies investigating the role of 
GRB10 in fetal growth except one study (225). We therefore focussed on analysing placental 
expression of GRB10 in our cohort of women with normal, small and large neonates. This is the 
same cohort where the IGF system related genes was investigated. Compared to normal controls, 
GRB10 mRNA expression was found to be overexpressed in SGAs but not in LGA neonates 
(Figure 5.1, A). The protein expression also supported the findings of the mRNA expression 
(Figure 5.1, B) in the SGA and the LGA group. 
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Figure 5.1 Placental GRB10 mRNA and protein expression in fetal growth disorders.   
(A) Placental GRB10 mRNA expression in normal (n = 37), SGA (n = 16) and LGA (n = 20) neonates, (B) 
Representative western blot and densitometry of placental GRB10 (67kDa) in SGA (n = 16), **p<0.05, **p<0.005 
vs. normal controls, mean ±SEM, Mann Whitney. Control with β-actin (42kDa) to correct for protein loading.   
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5.3. Correlation between placental GRB10 expression and birthweight percentiles  
 
Mouse studies have established the role of GRB10 in placental and fetal growth (167,221). To 
understand the association between GRB10 gene expression and birthweight percentiles in our 
cohort we investigated the correlation between GRB10 gene expression and birthweight 
percentiles. A negative correlation was seen; however this did not achieve significance (Figure 
5.2). 
 
 
 
 
Figure 5.2 Correlation between placental GRB10 mRNA expression and birthweight percentiles.  
                   Rs = -0.13, p = 0.3, Rs = Spearman’s coefficient 
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5.4. Placental GRB10 mRNA expression in women with GDM 
 
It has been shown that GRB10 is a candidate gene for the development of type 2 diabetes 
mellitus (227,228). Animal studies investigating GRB10 knockout in mice has shown to 
improve insulin sensitivity and also enhanced insulin stimulated AKT and mitogen-activated 
protein kinase phosphorylation (224). Therefore GRB10 can be considered as a negative 
regulator of insulin signalling. Since the role of GRB10 in the diabetic placenta has not been 
studied, we focussed on understanding if GRB10 was differentially regulated in the placentae of 
women affected by GDM. We did not find any significant difference in GRB10 expression in 
women with GDM as whole cohort (5.3, A) or in GDM on different treatments (Figure 5.3, B). 
 
 
Normal GDM
0.0
0.2
0.4
0.6
0.8
1.0
G
R
B
1
0
 r
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
s
s
io
n
Normal Diet Metformin Insulin
0.0
0.5
1.0
1.5
G
R
B
1
0
 r
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
s
s
io
n
 
 
Figure 5.3 Placental GRB10 mRNA expression in GDM. 
(A) The expression of GRB10 normal controls (n = 37) and in women with GDM (n = 60) irrespective of treatment. 
p = 0.9. (B) The expression of GRB10 in normal controls and in women with GDM on diet (n = 23), metformin (n 
= 23) or insulin (n = 14), p (overall) = 0.23, mean ±SEM, Mann Whitney.   
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5.5. Placental GRB10 methylation in fetal growth disorders 
 
Having shown a correlation between altered methylation and gene expression in fetuses with 
growth disorders we addressed if the same correlation existed for GRB10.  Seven CPGs were 
targeted on the promoter 500bp upstream of the transcription start site (Figure 5.4, A). 
Compared to controls, all the seven CpGs were hypomethylated in the SGAs but there were no 
methylation differences in the LGAs (Figure 5.4, B to H).  
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Figure 5.4 Identification of CpGs and analysing placental GRB10 methylation differences in normal,     
                  SGA and LGA neonates  
(A) CpGs identified 500bp upstream of transcription start site (TSS). Distances of CpG from TSS – CpG48  
location – Chr7: 50861253; CpG49 location – Chr7: 50861271; CpG50 location – Chr7: 50861285; CpG51 
location - Chr7: 50861303; CpG52 location - Chr7: 50861333; CpG53 location - Chr7:50861348; CpG54 location - 
Chr7:50861350 (B) CpG48 (C) CpG49, (D) CpG50, (E) CpG51, (F) CpG52, (G) CpG 53, (H) CpG 54. All CpGs 
were hypomethylated in placentae of SGA neonates (n = 9), *p<0.05, **p<0.005 vs. normal controls, mean ±SEM, 
Mann Whitney (n = 9 in each group).  
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5.5.1. Correlation between GRB10 methylation and gene expression 
 
Having established a negative correlation between mRNA expression and DNA methylation in 
non-imprinted genes in fetal growth disorders we wanted to test if a similar association existed 
for GRB10. The DNA methylation at all the seven CpG sites showed a trend towards negative 
correlation to the mRNA expression (Table 5.1).  
 
CpGs Rs P 
CpG48 -0.18 0.38 
CpG49 -0.07 0.73 
CpG50 -0.13 0.54 
CpG51 -0.15 0.46 
CpG52 -0.31 0.13 
CpG53 -0.11 0.33 
CpG54 -0.19 0.24 
 
 
Table 5.1 Correlation between GRB10 methylation and mRNA expression 
Rs = Spearman’s coefficient, p<0.05 = significant. 
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5.5.2. Correlation between GRB10 methylation and birthweight percentiles 
 
There is limited human data on methylation analysis of GRB10 in placenta or cord blood. A 
bivariate correlation between all the seven CpG sites on the GRB10 promoter revealed a 
significant positive correlation with increasing birthweight percentiles (Table 5.2). 
 
CpGs Rs P 
CpG48 0.77 <0.0001 
CpG49 0.78 <0.0001 
CpG50 0.73 <0.0001 
CpG51 0.68 0.0002 
CpG52 0.60 0.001 
CpG53 0.62 0.001 
CpG54 0.65 0.005 
 
Table 5.2 Correlation between GRB10 methylation and birthweight percentiles 
Rs = Spearman’s coefficient, p<0.05 = significant. 
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5.6. Umbilical cord levels of GRB10 in with fetal growth disorders  
 
We have shown differential epigenetic and genetic expression of placental GRB10 in fetal 
growth disorders. We therefore decided to investigate the GRB10 levels in the umbilical cord. 
Umbilical cord levels of GRB10 have not been investigated before hence this gave us the 
opportunity to not only analyse the levels in the fetal circulation but also understand if the levels 
follow a similar tend as the placental gene expression. No significant differences were found in 
the umbilical GRB10 levels in any of the subgroups (Figure 5.5). 
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Figure 5.5 GRB10 umbilical levels in normal, SGA and LGA neonates. (n=39) Mean ±SEM, Mann Whitney, p 
(overall) = 0.31 
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5.7. Correlation between umbilical levels of GRB10 and birthweight percentiles  
 
We have identified a significant positive correlation between IGF1 and birthweight percentiles 
and a significant negative correlation between the binding proteins and birthweight percentiles in 
the fetal growth cohort. We therefore wanted to test the correlation between GRB10 levels and 
birthweight percentiles in this cohort. There was no significant association between umbilical 
GBR10 levels and birthweight percentiles (Rs = 0.06, p = 0.71) (Figure 5.6). 
 
 
 
Figure 5.6 Correlation between GRB10 umbilical levels and birthweight percentiles 
Rs = 0.06, p = 0.7, Rs = Spearman’s coefficient, p<0.05 =significant 
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5.8. Summary and Discussion 
 
The imprinted gene GRB10 is unique in that it is paternally expressed in the brain but maternally 
expressed in the placenta (170). The maternal expression of GRB10 is especially important in 
the villous trophoblasts since it is involved in nutrient transfer and therefore plays a very crucial 
role in placental and fetal growth. Our study has shown that GRB10 is upregulated in the SGA 
neonates but it is not differentially expressed in the LGA neonates. We found a negative 
correlation between its gene expression and birthweight percentiles. One of the mechanisms by 
which genes are imprinted or silenced is by DNA methylation The CpGs in the GRB10 promoter 
were found to be hypomethylated in the placentae of SGA neonates and positively correlated 
with the birthweight percentiles. It is known that imprinted genes are silenced by DNA 
methylation and it is possible that alterations in imprinting may be playing a role in the 
pathogenesis of fetal growth restriction. We did not find methylation differences in the 
promoters of GRB10 in the LGA infants. This could be due to the targeted CpGs being under the 
influence of insulin resistance which macrosomic neonates are known to be associated with. The 
umbilical cord levels of GRB10 did not show any differences in any of the subgroups which is 
not surprising since GRB10 is an intracellular mediator. We also could not find any association 
between the umbilical levels and birthweight percentiles thus suggesting differential control of 
the placental and fetal compartments. There were no differences in the GRB10 expression in 
women with GDM irrespective of their treatment hence methylation analysis was not studied in 
this cohort. In summary, our findings suggest that alterations in placental DNA methylation of 
an imprinted gene like GRB10 may play a role in the pathogenesis of fetal growth restriction. 
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6. Final Conclusions and Future Work 
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Final Conclusions  
Fetal growth is a result of a complex interplay between genetic, nutritional and environmental 
factors. Any deviation in the process of normal growth can result in significant perinatal 
morbidity which in turn can result in chronic diseases of adulthood (229). It has been shown that 
the intrauterine environment accounts for 62% variation of birthweight while fetal and maternal 
genes account for only 18% and 20% respectively (230). The IGF-IGFBP system related genes 
have been proposed to play a role in regulating fetal growth as suggested not only by animal 
studies but there is also human data of a homozygous partial IGF1 deletion resulting in severe 
IUGR and postnatal growth failure (178). Our study was aimed at investigating the entire 
complement of the IGF-IGFBP system related genes in small, normal and large sized neonates, 
women with GDM and those with raised BMI in the same cohort.  
 
We found placental IGF1 but not IGF2 expression to be downregulated in SGA neonates. Of all 
the IGFBPS, IGFBPS 1 to 4 are the most predominant in fetal tissues (231), however previous 
studies have mainly focussed on investigating IGFBP1 and IGFBP3 in fetal growth 
(27,191,232). We found placental expression of IGFBP1 to 4 to be upregulated in SGAs and 
downregulated in LGAs while the expression of IGFBP7 was increased in SGAs only.  This 
shows an inverse association of IGF1 with most of the binding proteins thus reinforcing the 
important role played by the IGF-IGFBP unit in regulating fetal growth. This is further 
reinforced by our finding of a significant positive correlation of IGF1 expression and a 
significant negative correlation of IGFBP1, IGFBP2, IGFBP3, IGFBP4 and IGFBP7 expression 
with increasing birthweight percentiles. The methylation analysis of most of the CpGs showed 
hypermethylation of IGF1 and hypomethylation of the IGFBP promoters which could explain 
the reduced expression of placental IGF1 and increased expression of the placental IGFBPs in 
the SGA neonates. This highlights the importance of epigenetic mechanisms in fetal growth 
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restriction. However methylation of the IGFBP promoters could not explain the decreased 
expression of the IGFBPs in the LGA neonates. The umbilical IGF1 and IGFBP levels followed 
a similar trend of the placental gene expression profile. The umbilical levels of IGFBP1 and 
IGFBP4 were lower in the LGA and IGFBP2 and IGFBP3 were higher in the SGA group. 
Although the IGF axis will be differently regulated in the maternal and fetal compartments our 
findings of a similar trend of the umbilical circulatory levels to the placental expression changes 
may suggest a similar mechanism to regulate fetal growth.  
 
The IGF-IGFBP axis is not only regulated by insulin but also by nutrition and therefore is likely 
to play an important role in the pathogenesis of GDM. We found IGF1, IGFBP1 and IGFBP2 to 
be downregulated in women with GDM on diet and metformin but not in those on insulin. This 
may suggest an endocrine role of insulin to improve insulin insensitivity resulting in an 
upregulation of gene expression. The promoters of IGF1, IGFBP1 and IGFBP2 were found to be 
hypermethylated in women on diet treatment only and not for those on metformin or insulin. 
Although drugs are known to alter epigenetic profile (233), this finding could have an indirect 
association with altered glucose levels. This can be hypothesized especially since glucose is 
known to cross the placenta and altered glucose levels are known to affect DNA methylation 
(234). The significant negative correlation between IGF1, IGFBP1 and IGFBP2 promoter 
methylation and their respective gene expression which was seen in the non-diabetic placenta of 
small and large neonates was not observed when investigated in the diabetic placenta. Similarly 
the significant correlation between methylation of IGF1, IGFBP1 and IGFBP2 and birthweight 
percentiles found in fetal growth disorder cohort was also lost in the diabetic cohort. It is 
possible that these loci could still regulate transcription but they might also be sensitive to 
altered glucose levels. We found IGF1, IGFBP1 and IGFBP2 promoter methylation to be 
negatively correlated to fasting glucose levels at the 28 weeks OGTT, i.e. before the treatment 
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for GDM begins. Despite regular monitoring and treatment of these women, the epigenetic 
programming persisted until delivery which supports the theory that altered glucose levels can 
lead to long term epigenetic changes (207). The umbilical levels of IGF1, IGFBP1 and IGFBP2 
were found to be increased in GDM irrespective of treatment and contrary to the placental gene 
expression findings. It is likely that these levels are under the control of the fetal IGF axis it 
could be hypothesised that the increased umbilical levels are part of a fetal counter-regulatory 
response to the maternal diabetic environment. 
 
Imprinted genes have been implicated to play a crucial role in fetal growth (235). Previous 
studies have suggested a link between DNA methylation and altered expression of imprinted 
genes in response to fetal growth restriction (236,237). Gene expression analysis by microarray 
has suggested that hundreds of affected genes in intrauterine growth restriction (IUGR) were 
non-imprinted, while only a few were imprinted (238). Published data on expression of 
imprinted genes and IUGR is limited but PHLDA2, MEST, MEG3, GNAS, PLAG1 and PEG10 
have been the most commonly investigated (238–241). There is little evidence of human 
placental GRB10 expression in fetal growth disorders however mice studies (167,221) have 
consistently shown the role played by GRB10 in growth suppression. This is supported by the 
findings of our study where GRB10 mRNA and protein expression was significantly higher in 
SGA neonates. The GRB10 promoter was found to be hypomethylated in SGA placentae with 
no methylation differences in the LGAs. It has been reported that DNA methylation can be 
altered by glucose levels (207,234) and macrosomic infants are likely to be insulin resistant 
(242). This may explain the altered GRB10 methylation and gene expression in LGA neonates 
especially since it has been shown that GRB10 is a regulator of insulin (217).  
 
 
146 
 
Future Work 
 
Fetal growth disorders  
 
We have highlighted the importance of DNA methylation in fetal growth restriction however the 
pathogenesis of macrosomia could not be explained by this epigenetic mechanism. It is therefore 
possible that other epigenetic mechanisms could be playing a role in the pathogenesis of 
macrosomia and this could be investigated as part of future work. Further studies could also 
investigate methylation of additional CpGs in the promoter region and possibly unearth the 
CpGs that are relevant for influencing macrosomia. It will also be useful future work to study 
whether there are corresponding epigenetic and gene expression changes in the IGF1 and IGF2 
receptors in small and macrosomic neonates. The umbilical levels of the IGF system related 
proteins followed a similar trend to their respective placental gene expression changes. Future 
work can therefore include investigating the methylation profile of the IGF axis in the fetal 
blood which may help us understand if the altered circulating levels are epigenetically driven in 
the fetus as well.   
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Gestational diabetes  
 
Future work could include analysing IGF1, IGFBP1 and IGFBP2 methylation levels in the 
maternal blood at 28 weeks gestation, i.e. at the time of the OGTT and also at the time of 
delivery. This could help understand the correlation between altered maternal glucose levels and 
maternal methylation, and whether this correlation follows the trend of the negative correlation 
between maternal glucose levels and the placental epigenetic profile. Analysing umbilical 
methylation levels of IGF1, IGFBP1 and IGFBP2 genes in the neonates of mothers with GDM, 
may be useful to understand if epigenetic control is exerted by the fetus in altering these levels.  
 
Transcription factor binding  
 
In silico analysis identified several transcription factors which could potentially bind at the target 
CpGs. Some of them have been shown to be present in the placenta, altered by epigenetic 
mechanisms and also implicated in adult diseases (198,200,243–245). Several of these 
transcription factors have been already identified in the placental trophoblast (246). Future work 
should include identification of placental transcription factors which are known to play a key 
role in expression of IGF system related genes. Electromobility Shift DNA assays (EMSAs) or 
Chromatin immunoprecipitation (CHIP) analysis can be performed to investigate if DNA 
methylation alters binding of these transcription factors to the target CpGs. These investigations 
may shed more light on the interplay between the placental transcription factors, DNA 
methylation and their role in fetal growth.   
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Role of GRB10 
 
We found differential methylation and gene expression changes of the GRB10 gene and fetal 
growth. It is known that DNA methylation plays a role in gene imprinting therefore whether the 
GRB10 hypomethylation in SGA is related to alterations in imprinting can be investigated in the 
future. It is known that GRB10 is a regulator of insulin therefore its role in insulin receptor 
signalling in the placenta can be explored in the future.  
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